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Primary aldosteronism (PA) is the most common cause of secondary hypertension 
(HT), accounting for 5 to 12% of all hypertensive individuals. Patients with PA 
experience increased cardiovascular, renal and metabolic complications and have 
impaired quality of life compared with essential HT. We aimed to determine the 
clinical and biochemical characteristics of the PA population in Western Norway, to 
identify the optimal diagnostic procedures, and to evaluate long-term treatment 
outcome after medical and surgical treatment.  
Three clinical studies were conducted. We retrospectively identified all PA patients 
admitted to Haukeland University Hospital from 1998 to 2012, a total of 108 cases. 
The majority had unilateral PA and hypokalaemia, indicating that mostly patients 
with florid PA were detected. Cure rate of HT after adrenalectomy was low. Female 
sex, presence of somatic KCNJ5 mutations and a histopathological adenoma were 
associated with cure of HT. 
We also conducted an adrenal vein sampling (AVS) study, where we found that the 
use of intraprocedural point-of-care cortisol assay increased the AVS success rate 
substantially compared with historical controls.  
In our cardiac magnetic resonance imaging (CMR) study, we found that left 
ventricular (LV) mass decreased rapidly after PA treatment, most pronounced in 
adrenalectomised patients. Dynamic contrast enhancement and T1 mapping did not 
reveal increase in myocardial fibrosis in PA compared with healthy subjects. 
In conclusion, PA is probably grossly underdiagnosed in Norway, in particular 
bilateral PA, which often exhibits a mild phenotype. HT cure rate after adrenalectomy 
was low. Intraprocedural cortisol assay increased the success rate of AVS, and is now 
in routine clinical use at our centre. Specific PA treatment rapidly reduced LV mass, 
underlining the importance of correct diagnosis allowing for efficient treatment. 
Although cardiovascular risk is increased in PA, myocardial fibrosis may not 
represent a common clinical problem.  
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1 Introduction 
1.1 Normal physiology of the adrenals – historical perspectives 
The anatomy of the adrenal glands was first described by Barholomeo Eustachius in 
1563, but their functional role was not defined until the 19th century. Thomas 
Addison described both the clinical features and pathological findings in primary 
adrenal insufficiency (Addison’s disease) in 1855. Shortly after Charles E Brown-
Séquard by performing adrenalectomy in dogs, cats and guinea pigs, demonstrated 
that the adrenal glands were essential for life (1). Between 1937 and 1955 the 
different adrenocortical steroid hormones were isolated and synthesised. Sylvia A 
Simpson and James F Tait isolated aldosterone in 1953 (2). In 1954, the symptoms 
and signs of primary aldosteronism (PA) were described for the first time by Jerome 
Conn (3). More than three decades later, in 1987, Jeff Arriza cloned and characterised 
the mineralocorticoid receptor (MR) (4). Aldosterone and cortisol have similar 
binding affinity for the MR, but cortisol circulates at much higher concentrations than 
aldosterone. The tissue specificity of the MR to aldosterone was therefore a mystery 
until Christopher RW Edwards and John W Funder in 1988 simultaneously showed 
that tissue specific expression of the enzyme 11β-hydroxysteroid dehydrogenase type 
2 (11β- HSD2) conferred specificity of the MR to aldosterone and not cortisol (5, 6). 
1.2 Aldosterone synthesis and regulation 
Aldosterone is an adrenal steroid hormone that is synthesised in the outermost layer 
of the adrenal cortex, the zona glomerulosa (ZG). The other main types of hormones 
synthesised in the adrenal cortex are the glucocorticoid cortisol in the zona fasciculata 
(ZF), and the sex steroids, mainly androgens, synthesised in the innermost layer of 
the adrenal cortex, the zona reticularis (ZR). The precursor of all steroid hormones 
produced by the adrenal cortex is cholesterol, with zone specific expression of the 
different enzymes. The biosynthetic pathways of the steroidogenesis of aldosterone, 
cortisol and androgens are shown in Figure 1. 
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Figure 1 Adrenal steroidogenesis. Modified from Stowasser et al, Physiol Rev. volume 96, 2016, and others.
The initial and rate-limiting step of all adrenal steroidogenesis is the transport of 
intracellular cholesterol from the outer to the inner mitochondrial membrane by 
steroidogenic acute regulatory protein (StAR), for conversion to pregnenolone. In the 
endoplasmatic reticulum pregnenolone is converted to progesterone, and further to 
deoxycorticosterone. The final three steps of aldosterone biosynthesis occur in the 
mitochondria, where deoxycorticosterone undergoes 11-hydroxylation, 18-
hydroxylation and 18-oxidation, all three steps catalysed by aldosterone synthase, 
encoded by CYP11B2. Aldosterone synthase is expressed exclusively in the ZG. The 
enzyme is highly homologous with 11β-hydroxylase (encoded by CYP11B1), 
expressed in ZF and responsible for the final steps of cortisol biosynthesis (7).  
18-Hydroxycortisol and 18-oxocortisol are hybrid steroids with structural
characteristics of both cortisol and aldosterone.  They are both produced by 
aldosterone synthase using the cortisol precursor 11-deoxycortisol as substrate.  
Production of 18-hydroxycortisol and 18-oxocortisol is normally extremely low, due 
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to functional zonation of the adrenal cortex, with 11-deoxycortisol present in the ZF 
and aldosterone synthase expressed in the ZG (8, 9).  
The main stimulatory regulator of aldosterone synthesis is angiotensin II via the 
renin-angiotensin-aldosterone system (RAAS) (Figure 2), but elevation of plasma 
potassium and adrenocorticotropic hormone (ACTH) also stimulate aldosterone 
synthesis.   
 
Figure 2 Renin-angiotensin-aldosterone system. Patel et al: Role of radiology in the management of primary 
aldosteronism, Radiographics 2007; 27(4):1145-1157. Reprinted with permission.  
Renin is an enzyme produced by the juxtaglomerular cells of the kidney. It causes 
cleavage of angiotensinogen originating in the liver, to the inactive peptide 
angiotensin I. This is the rate-limiting step of the RAAS. Angiotensin converting 
enzyme (ACE), predominantly expressed in the lungs, further cleaves angiotensin I to 
angiotensin II, the active hormone. Binding of angiotensin II to type 1 angiotensin II 
receptors of the membrane of ZG cells stimulates aldosterone synthesis. Angiotensin 
II also mediates arteriolar vasoconstriction, leading to increase in systemic vascular 
resistance and systemic blood pressure (BP).  
Principal stimulators of renin secretion include: 1) reduced perfusion pressure sensed 
by baroreceptors in the wall of the afferent arteriole of the glomerulus, 2) reduction of 
sodium chloride delivery to the cells of the macula densa in the early distal tubuli, 
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and 3) sympathetic activation of the renin-secreting juxtaglomerular cells. Thus, renin 
secretion is stimulated in clinical situations with sodium and/or volume depletion, 
acute drop in BP, stress or change of posture to the upright position, or renal artery 
stenosis. Moreover, pharmacological blockage of the RAAS by ACE inhibitors or 
angiotensin II receptor blockers also increases renin. Conversely, renin is inhibited by 
sodium retention or extracellular volume expansion, by renal conditions associated 
with abnormal retention of sodium, by aging and chronic kidney disease, which 
reduce the renin-producing capacity. Also pharmacological agents reducing 
sympathetic activation (e.g. β-adrenergic blockers) reduce renin. Furthermore, 
angiotensin II exerts negative feedback on renin secretion, by way of arteriolar 
vasoconstriction and sodium reabsorption via aldosterone secretion. Renin secretion 
follows a diurnal rhythm, with a peak of secretion between 2 a.m. and 8 a.m. (10). 
In addition to the systemic RAAS, local RAAS operate in various tissues, including 
the heart, vasculature, adrenal glands, central nervous system, skin, intestine and 
adipose tissue. Here, local angiotensin II may cause both autocrine and paracrine 
physiological and pathophysiological effects (11, 12).  
Besides stimulation by RAAS, aldosterone synthesis is stimulated by increase in 
plasma potassium both acutely and in the long term. Conversely, hypokalemia 
reduces aldosterone secretion. The responsiveness of ZG cells to potassium levels is 
retained even in conditions where aldosterone synthesis is autonomous, that is, not 
sensitive to angiotensin II levels. ACTH secreted by the pituitary gland may also 
weakly stimulate aldosterone secretion acutely, but transiently. Thus, stress-induced 
rise in ACTH may cause transient rise in aldosterone. ACTH exhibits a diurnal 
rhythm, with a peak between 5 a.m. and 9 a.m. (13). Under physiological 
circumstances, aldosterone synthesis shows a circadian rhythm parallel to, but 
preceding that of cortisol, with the most prominent aldosterone secretion occurring at 
night during recumbency. The underlying regulatory mechanisms are still unknown 
(14, 15). 
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Apart from the major regulators angiotensin II, potassium and ACTH, several other 
regulators may cause minor effect on aldosterone secretion, such as atrial natriuretic 
peptide (ANP), estrogens, vasopressin and parathyroid hormone (PTH) (16-19).   
1.3 Aldosterone effects 
Aldosterone’s main action is in the kidney, where it stimulates sodium reabsorption 
in the epithelial cells of the distal nephron. Water is retained with the osmotically 
active sodium ions, causing extracellular volume expansion and increase in blood 
pressure. Sodium reabsorption is accompanied by increased potassium and hydrogen 
ion excretion. Similar actions of aldosterone occur in epithelial cells of the distal 
colon and sweat glands. These aldosterone effects are mediated by the intracellular 
MR. The MR has similar binding affinity for and can also be activated by cortisol, 
which is present in plasma concentrations about 1000-fold greater than those of 
aldosterone. However, in epithelial cells as in the kidney the enzyme11β- HSD2 
inactivates cortisol to the inactive metabolite cortisone, and prevents a 
mineralocorticoid excess state (5, 6, 20) .  
The MR is also present in a range of non-epithelial tissues including endothelial cells, 
vascular smooth muscle, adipocytes, macrophages, cardiomyocytes, and in the central 
nervous system (21). The MR in non-epithelial tissues, with the exception of blood 
vessels, lack 11β- HSD2, thus normal cortisol levels occupy the majority of MR, 
exerting an inhibitory effect on MR activity under normal circumstances (10, 22). 
However, under conditions of tissue inflammation and hypoxia, cortisol becomes an 
MR agonist.  
The classical effects of aldosterone are normally seen after hours, and are mediated 
by MR-mediated gene transcription. In addition, rapid non-genomic effects of 
aldosterone have been demonstrated in the kidneys, the heart and the vascular wall 
that involve different signaling pathways (23, 24). 
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1.4 Primary aldosteronism, definition and epidemiology 
PA is a pathological condition where the secretion of aldosterone from the adrenal 
glands is excessive in relation to the body’s sodium and volume status, and 
autonomous of its normal regulation by the RAAS. Its main clinical manifestation is 
hypertension (HT), with or without concomitant hypokalaemia. PA was first 
described by Jerome Conn in 1954, through studies of a 34-year old hypertensive 
woman with florid signs and symptoms indicative of excessive aldosterone (3). She 
had a 7-year history of muscle spasms, temporary paralysis, tetany and weakness, a 4-
year history of HT, and she presented with HT, severe hypokalaemia and metabolic 
alkalosis. Conn suspected that her symptoms and signs were caused by excess 
secretion of aldosterone, and planned for bilateral adrenalectomy. However, during 
surgery, a large tumour in the right adrenal gland was encountered and removed, and 
the contralateral adrenal gland was left intact. Postoperatively, both the patient’s 
metabolic abnormalities and clinical signs were almost totally reversed. PA is 
therefore also called Conn’s syndrome, in recognition of Jerome Conn.  
Although Conn himself predicted PA to be a relatively common disease, until the 
early 1990s, PA was considered to be rare, accounting for less than 1% of all 
hypertensive patients. However, after the introduction of aldosterone-renin-ratio 
(ARR) as a screening method in 1981 (25),  it has become evident that PA is a highly 
prevalent cause of secondary HT, accounting for between 5-12% of all HT, with the 
majority of patients being normokalaemic. Nonetheless, wide variations in prevalence 
(1-30%) are reported in different studies (26-28). The prevalence of PA depends both 
on the population examined, the degree of HT and the stringency of the diagnostic 
criteria. Reported prevalence is around 4-6% in stage 1 HT in primary care patients 
and about 11% in referral centres, while among patients with resistant HT prevalence 
numbers up to 20-24% have been reported (27, 29-32).  
Recently, PA has also been described in normo- and prehypertensive cohorts in Asia, 
Europe and USA. (33-35). One was a longitudinal study which demonstrated that 
normotensive individuals with confirmed PA had an increased risk of developing HT 
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at five years, compared with controls without PA (34). Another study examining 
normotensive individuals with suppressed renin levels, found that 14% had 
autonomous aldosterone secretion that fulfilled confirmatory criteria for PA, although 
ARR levels were not different from those who did not fulfill the diagnostic criteria 
(35). Thus, renin-independent autonomous aldosteronism represents a continuum 
ranging from low-renin in normotension, through low-renin HT to classical PA.      
1.5 Subtypes and genetics in PA 
The two most common subtypes of PA are aldosterone-producing adenoma (APA) 
and idiopathic hyperaldosteronism (IHA). APA is usually unilateral, accounting for 
about 28 - 50%, whereas IHA mostly has bilateral ZG hyperplasia, also termed 
bilateral adrenal hyperplasia (BAH), and accounts for about 50-70% (26, 27, 29). 
However, these traditional main subtypes reveal a wide diversity in adrenal 
morphology. In an adrenal with APA, the remaining cortex may contain additional, 
smaller nodules, and the surrounding ZG may show diffuse hyperplasia. Unilateral 
hyperplasia without APA may also occur (36). In IHA, the hyperplasia may be 
diffuse, micro- or macronodular (10). Very rare subtypes of PA are aldosterone-
producing carcinoma (<1%) and ectopic aldosterone-producing adenoma or 
carcinoma (<0.1% of all PA) (37). 
Recently, major insights have emerged into the pathogenesis and genetic causes of 
PA Familial forms of hyperaldosteronism (FH) are rare, but at least four different 
types exist. FH-I, also called glucocorticoid-remediable aldosteronism (GRA), was 
first described in 1966 (38). It is inherited in an autosomal dominant fashion, and is 
caused by a chimeric CYP11B1/CYP11B2 gene responsive to ACTH rather than 
angiotensin II, first elucidated in 1992 (39). GRA has a presumed prevalence of 0.7-
1.0% of all PA (7). FH-II, first described in 1991, is also autosomal dominant, but the 
genetic basis is still unclear, and it is clinically indistinguishable from non-familial 
PA (7, 40). It is diagnosed when two or more members of the same family are 
affected. Prevalence estimates of FH-II vary from 3% to 7% of all PA. In 2008, FH-
III was described, and the causative germline mutation in the KCNJ5-gene encoding 
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the potassium channel Kir 3.4 was found in 2011 (41, 42). Affected families reveal a 
phenotypic heterogeneity, ranging from early-onset treatment-resistant HT and 
profound hypokalaemia, to milder phenotypes (7). A germline mutation in the 
CACNAID gene encoding the calcium channel subunit was discovered in 2013 in two 
children with PA and neuromuscular abnormalities (43). FH-IV, first described in 
2015, is due to mutations in the CACNAIH gene, which encodes a voltage-gated 
calcium channel (44). Affected patients all presented with HT by the age of 10.  
Much more common are somatic mutations in APAs. Pathogenetic somatic mutations 
in KCNJ5 were first reported in 2011 (42). Discoveries of disease-causing somatic 
mutations in the sodium/potassium ATPase ATP1A1, the calcium ATPase ATP2B3 
genes, and in the CACNA1D gene, all followed in 2013 (43, 45). Functional 
characterisations revealed that the mutated variants found in APAs caused elevation 
of intracellular calcium in adrenocortical cells, followed by aldosterone synthase 
overexpression and aldosterone overproduction. Recently, somatic mutations in the 
CTNNB1gene encoding β-catenin in the Wnt signaling pathway have been reported 
both in APAs and in other adrenocortical tumours, but the role of CTNNB1mutations 
in APA pathogenesis is still unclear (46, 47).  
Somatic mutations in KCNJ5 are found in 34-54% of APAs in Caucasians patients, 
and even more frequently in Asian populations. Patients with KCNJ5 mutations are 
more often female, younger and have more florid PA. The tumours are larger than 
patients without KCNJ5 mutations, and tend to have higher proportions of clear ZF-
like cells. Somatic mutations in ATP1A1, ATP2B3 and CACNAID genes are more 
frequent in males, with small APAs predominantly containing ZG-like cells. Somatic 
ATP1A1 gene mutations have been found in 1-6% of APAs, mutations in ATP2B3 in 
1-3% and mutations in the CACNAID gene in 1-9%. CTNNB1mutations are found in 
2-5% of APAs, often in older patients with a shorter duration of HT, and a lower HT 
cure rate than KCNJ5 mutation carriers and those without identified mutations (47-
57). However, genotype-phenotype correlations have been inconsistent across 
different studies.  
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Recently, functional histopathology with immunohistochemistry has uncovered a 
significant histological complexity. Specific monoclonal antibodies against the 
aldosterone synthase were first introduced in 2014 (58). APAs may demonstrate 
intra-tumour heterogeneity with wide variation in functional histopathological 
features, exhibiting a wide complexity of aldosterone synthase staining and co-
expression of various steroidogenic enzymes. In addition, aldosterone synthase-
positive micronodules or aldosterone-producing cell clusters (APCC) with strong 
immunoreactivity for aldosterone synthase are frequently present, and harbour 
somatic mutations in genes associated with APA, although not KCNJ5 mutations (59-
64). This variation in histopathological features of adenomas and concurrent presence 
of APCCs has led to the hypothesis that many cases of unilateral PA might represent 
bilateral asymmetric hyperplasia with steroidogenically active nodules due to somatic 
mutations (36).  
Most patients with IHA are angiotensin II responsive, defined as a rise of plasma 
aldosterone at least 50% during 2-3 hours of upright posture after overnight 
recumbency, or during a one hour infusion of angiotensin II. APAs were initially 
thought exclusively angiotensin II-unresponsive, but later studies have shown that up 
to 50% of APAs are angiotensin II-responsive. Differences in cellular composition 
between angiotensin II-responsive and -unresponsive APAs have been found in some, 
but not all studies. Most consistently, angiotensin II-unresponsive APAs are 
composed predominantly of ZF-like cells, whereas angiotensin II-responsive APAs 
contain more ZG-like cells (65-67). 
1.6 Clinical manifestations and end-organ damage 
The main clinical manifestation of PA is HT. Hypokalaemia, previously considered a 
major characteristic of PA, was found in only 9-37% in large patient cohorts (26, 27).  
Higher proportions were reported in retrospective studies (68). Hypokalaemia is most 
common in APAs (27). Marked hypokalaemia may cause muscle weakness and 
cramps. The patients may experience polyuria and/or nocturia, which is caused by a 
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hypokalaemia-induced renal concentration defect (37). Nocturia is also common in 
normokalaemic patients, possibly due du a rise in ANP levels (10, 69).  
In addition to the effects on BP, chronic exposure of aldosterone excess causes 
deleterious effects in multiple organs, in particular the heart, kidneys and blood 
vessels.  
1.6.1 PA and cardiovascular damage 
Several clinical studies conducted in the general population have provided evidence 
of association between aldosterone levels and cardiac left ventricular (LV) 
hypertrophy and geometric remodeling. In the Framingham offspring study, the ARR 
was identified as a key correlate of concentric and eccentric LV hypertrophy (70). 
Similarly, in a study of patients with at least one risk factor for cardiovascular disease 
and preserved LV ejection fraction, aldosterone levels were positively correlated with 
increased LV mass index and wall thickness (71). A direct relationship between 
aldosterone levels and LV hypertrophy has also been found in several studies of 
patients with essential HT (72, 73) .  
In PA, echocardiographic and applanation tonometry studies have provided evidence 
of increased LV mass and LV hypertrophy greater than in essential HT. Similarly, 
increased diastolic dysfunction, endothelial dysfunction, carotid intima-media 
thickness, arterial wall stiffness,  femoral pulse wave velocity and myocardial and 
carotid artery ultrasonic backscatter signals indicative of fibrosis have been found 
(74-81). Newly diagnosed PA patients have a marked increase of cardiovascular 
events, including cerebral stroke, myocardial infarction, atrial fibrillation and heart 
failure.  Cardiovascular mortality is increased compared with matched patients with 
essential HT (82-88). A recent meta-analysis found no differences in cardiovascular 
events between patients with bilateral and unilateral PA (87). However, in a large 
multicenter study from Japan, hypokalaemia, unilateral PA, and a baseline 
aldosterone level above 350 pmol/L (125 pg/mL) were all associated with the highest 
risk of cardiovascular comorbidities (88). Thus, the most florid cases of PA 
experience the most cardiovascular events.  
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The myocardium comprises several cell populations (Figure 3). Cardiomyocytes 
occupy 75% of its structural place. In a pressure- and volume-overloaded heart, 
growth of cardiomyocytes causes left LV hypertrophy. The cardiac interstitium 
comprises endothelial cells lining the coronary and lymphatic vasculature and 
endocardium, vascular smooth muscle cells found in epicardial and intramyocardial 
coronary arteries and arterioles, cardiac fibroblasts, macrophages and mast cells. The 
fibroblasts are responsible for the synthesis of fibrillary collagens type I and III.  
Activation of cardiac fibroblast leads to abnormal accumulation of collagen which 
causes reactive interstitial fibrosis. These processes may lead to increased stiffness 
and pump dysfunction, first apparent during diastole. This reactive fibrosis differs 
from the focal replacement fibrosis (cardiac “scarring”) caused by cardiomyocyte 
necrosis (89, 90). 
 
The deleterious cardiac effects of aldosterone excess were first demonstrated in a 
landmark experimental animal study by Christian G Brilla and Karl T Weber in 1992, 
followed by several other animal studies. In these studies, chronic aldosterone 
infusion in the setting of a high-salt diet induced oxidative stress and caused 
myocardial and perivascular inflammation, accumulation of fibrillary collagen and 
subsequent interstitial and perivascular fibrosis independently of the BP effect (91-
94). These effects were attenuated by treatment with MR antagonists.  
Figure 3 Schematic representation of 
myocardium and its (cardio)myocyte and 
nonmyocyte cells and tissue fluid. Weber 
and Brilla; Pathological Hypertrophy and 
Cardiac interstitium. Fibrosis and renin-
angiotensin-aldosterone system, Circulation 




The cardiac responses to aldosterone are thought to be mediated by activation of the 
MR, which is present in the cardiomyocyte. However, expression of MR in 
fibroblasts is controversial, and MR stimulation may promote fibroblast collagen 
synthesis via paracrine effects (12). In human PA, echocardiographic 
videodensitometric and ultrasonic backscatter signal analyses have shown alterations 
in myocardial textures compared with essential HT, suggestive of increased collagen 
deposition (79-81). The increased frequency of sustained arrhythmias seen in PA, 
especially atrial fibrillation, is presumably caused by cardiac fibrosis and/or LV 
hypertrophy (82, 83).  
1.6.2 Cardiac magnetic resonance imaging 
Cardiac magnetic resonance imaging (CMR) is the recommended imaging modality 
for characterisation of myocardial tissue (95). It provides a highly accurate non-
invasive assessment of cardiac and vascular structure and function. In addition, CMR 
contrast enhancement techniques can detect irreversible myocardial focal fibrosis. 
The contrast agent gadolinium is prevented from crossing cell membranes due to its 
large molecular size. Following intravenous bolus administration, gadolinium 
accumulates in the extracellular space of the myocardium, and slowly disappears as it 
is cleared from the blood by the kidneys. The T1 relaxation time is a measure of the 
recovery of the nuclear spin magnetisation after a radiofrequency pulse in the CMR 
scanner, and is a key source of soft tissue contrast in CMR. Gadolinium shortens T1 
relaxation time proportionally to its concentration in the tissue.  Expansion of the 
extracellular space leads to a higher concentration of gadolinium, and will appear 
bright on inversion-recovery T1-weighted sequence. However, the most commonly 
used contrast enhancement technique, late gadolinium enhancement, requires a 
comparison between affected and unaffected myocardium. It is therefore less 
sensitive in detecting diffuse myocardial fibrosis affecting the whole myocardium, an 
early form of fibrosis which may be reversible. Several contrast enhancement 
quantification techniques do exist, but there is no universally accepted method, and 
sufficient validation for routine clinical use has not been performed (96, 97).  
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However, newer CMR T1 mapping techniques enable quantitative assessment of 
tissue composition and the detection of both focal and diffuse myocardial fibrosis, 
either by native T1 mapping or calculation of extracellular volume (ECV) percentage. 
ECV after gadolinium administration is used as a surrogate marker of the 
extracellular space, which is assumed to reflect diffuse myocardial fibrosis (95, 97).  
Two CMR studies both applying contrast enhancement techniques revealed results 
consistent with increased myocardial fibrosis in PA (98, 99). However, only one of 
those applied a quantitative contrast enhancement method (99). No CMR studies have 
so far applied T1 mapping in human PA. Thus, the degree of cardiac fibrosis induced 
by PA in humans has not been extensively studied and is still incompletely known. 
1.6.3 PA and renal damage 
Excessive aldosterone may also affect renal function. Renal parenchymal damage in 
renal biopsies of PA patients was first demonstrated in 1977 (100). PA patients 
demonstrate higher urinary albumin excretion rates and more often microalbuminuria, 
a marker of early renal involvement and a predictor of cardiovascular risk, than in 
essential HT. Whether the increased albumin excretion is caused by the 
haemodynamic load or represents a structural response to aldosterone/salt imbalance 
involving endothelial dysfunction and glomerular damage is not fully elucidated. The 
effects of PA on glomerular filtration rates have shown divergent results, with some 
studies showing glomerular hyperfiltration in untreated PA, while others found lower 
GFR compared with essential HT (101-104). 
1.6.4 PA and effects on glucose metabolism 
An association between aldosterone overproduction and abnormal glucose 
metabolism may also exist. In the Framingham offspring study, higher aldosterone 
concentrations were associated with future development of the metabolic syndrome 
(105). Both the metabolic syndrome and diabetes mellitus have been found more 
prevalent in PA than in essential HT in some, but not all studies (106-109). Possible 
mechanisms include both aldosterone-mediated impaired first-phase insulin secretion 
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from the pancreas, and increased insulin resistance caused by excess aldosterone 
(110-112). Moreover, concurrent glucocorticoid excess may have a role in altering 
glucose metabolism in PA, actualised by the recent finding that glucocorticoid excess 
in PA was closely linked with parameters of metabolic risk (113).  
1.6.5 PA and other complications 
Obstructive sleep apnoea is highly correlated with HT, and particularly treatment 
resistant HT. A particularly high prevalence of PA has been found in patients with 
obstructive sleep apnoea (114, 115). Aldosterone may worsen obstructive sleep 
apnoea by promoting accumulation of fluid within the neck area in the supine 
position, increasing upper airway resistance. Conversely, intermittent nocturnal 
hypoxia may active the RAAS (116).  
Coincident PA and primary hyperparathyroidism (PHPT) was reported in several 
studies, with increasing evidence supporting a bidirectional interaction between PTH 
and aldosterone (117, 118). The MR is expressed in the parathyroid gland, although 
the mechanisms by which aldosterone stimulates PTH are not exactly known (119). 
Similarly, PTH receptors are present in the adrenal cortex, with PTH causing release 
of both aldosterone and cortisol (120). Patients with PHPT have increased risk of HT 
and cardiovascular disease and patients with PA have lower bone mineral density and 
higher fracture rates than non-PA, which may be features of this relationship (121-
124). 
In addition to the target organ effects discussed above, aldosterone excess may also 
cause psychological effects. The MR is present in the brain, and accumulating 
evidence suggests that aldosterone may act selectively on the MR in relevant mood-
regulating brain areas, without competing with cortisol (125). Additionally, severe 
HT may in itself adversely affect quality of life (126). PA is associated with 
depression, anxiety disorders and impaired quality of life, with female PA patients 
having lower quality of life compared with men (127-130).  
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1.7 PA and concomitant glucocorticoid excess 
Concomitant PA and autonomous cortisol secretion may occur, although thought to 
be relatively rare (131, 132). If present, it may influence the clinical work-up, 
treatment and prognosis of PA. Recently, concomitant glucocorticoid hypersecretion 
in PA was found more frequently than expected, when measured as 24h urinary 
glucocorticoid output. In that study, the cortisol and total glucocorticoid metabolite 
excretions in PA were at least as high as in patients with autonomous cortisol 
secretion. Interestingly, for unclear reasons, few of the PA patients showed a 
pathological response to the overnight dexamethasone suppression test or increased 
late-night salivary cortisol, but plasma ACTH was in the low normal range. In 
addition, several surrogate parameters of metabolic risk correlated with the 
glucocorticoid output, but not mineralocorticoid output, indicating that glucocorticoid 
cosecretion contributes to the associated metabolic risk in PA. Glucocorticoid excess 
may also account for the increased risk of osteoporotic fractures and depression in PA 
(113). 
1.8 Aldosterone and sodium 
Dietary sodium intake strongly influences the adverse effects of aldosterone excess, 
both in experimental and clinical studies. An interaction between sodium and 
aldosterone was first demonstrated in 1992, when rats given chronic aldosterone 
infusion developed myocardial inflammation and subsequent fibrosis only in the 
setting of a concomitant high-sodium diet (91). Similarly, in populations with chronic 
sodium deficiency, extraordinarily  high aldosterone levels are present but not 
associated with BP or cardiovascular damage (133). In patients with essential HT, a 
significant relationship between LV mass and daily urinary sodium was found both 
before and after medical treatment that inhibited the RAAS (134). In human PA a 
high-sodium diet is associated with both greater LV mass and worsened proteinuria. 
Reduction in LV mass after specific PA treatment is greater when dietary sodium 
intake is reduced (135-137).  
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1.9 Diagnostic workup 
Clinical guidelines for case detection, diagnosis and treatment of PA were published 
by the Endocrine Society in 2008, and updated in 2016 (138, 139). The diagnostic 
workup comprises three phases: screening (case detection), confirmatory testing and 
subtype differentiation (Figure 4).  
1.9.1 Screening 
Screening is recommended in the patient groups shown in Figure 5, all considered to 
have increased risk of PA.  
The ARR is recommended as the preferred screening test, as it is more sensitive for 
detection of PA than both potassium and aldosterone levels, and more specific than  
isolated renin measurements (25, 140). Both aldosterone and renin are affected both 
by posture and time of day. ARR testing should be performed in the morning, 
Figure 4 Algorithm for the detection, 
confirmation, subtype testing and 
treatment of PA. Modified from 
Funder et al: The Management of 
Primary Aldosteronism: Case 
Detection, Diagnosis and Treatment: 
An Endocrine Society Clinical Practice 
Guideline, JCEM 2016, 101(5): 1889-
1916. 
Figure 5 Patient groups in which 
case detection for PA is 
recommended. Modified from Funder 
et al: The Management of Primary 
Aldosteronism: Case Detection, 
Diagnosis and Treatment: An 
Endocrine Society Clinical Practice 
Guideline, JCEM 2016, 101(5): 1889-
1916 
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minimum with two hours out of bed, and then seated for 5-15 minutes. If possible, 
antihypertensive medication interfering on the RAAS system and non-steroidal anti-
inflammatory drugs (NSAIDs) should be withdrawn before testing, and replaced with 
non-interfering medication, as recommended in the guidelines (Table 1) (139).  
Products derived from licorice root that inhibit the enzyme 11β-HSD2, should 
additionally be withdrawn for at least four weeks. Verapamil slow-release and α-
adrenergic blockers have minimal effects on the ARR and can be used to control BP 
in this period. Recently, moxonidine was shown not to interfere significantly with the 
ARR, and may therefore also be used during screening (141). Potassium status is 
important: hypokalaemia suppresses aldosterone and must be replenished. Sodium 
intake should be unrestricted during testing. Other factors that may influence the 
ARR are estrogen-containing medication, gender, menstrual cycle phase, selective 
serotonin reuptake inhibitor antidepressants, renal failure and old age (142-146) .  










β-adrenergic blockers ↓↓   ↓ ↑ 2 weeks 
Central α-agonists ↓↓        ↓↓↑ ↑ 2 weeks 
Potassium-wasting diuretics ↑↑ →↑ ↓ 4 weeks 
Potassium-sparing diuretics          
(MR antagonists, amiloride) 
↑↑   ↑ ↓ 4 weeks 
ACE inhibitors ↑↑   ↓ ↓ 2 weeks 
Angiotensin II receptor 
blockers 
↑↑   ↓ ↓ 2 weeks 
Calcium channel antagonists 
(dihydropyridines) 
↑ →↓ ↓ 2 weeks 
Renin inhibitors ↓↑*   ↓ ↑↓* 2 weeks 
NSAIDs ↓↓   ↓ ↑ 2 weeks 
Table 1 Medication that may lead to false-positive or false- negative ARR results, and recommended 
period of withdrawal. *Renin inhibitors lower plasma renin-activity (PRA), but increase direct renin-
concentration (DRC). ARR increases when PRA is used, and is lowered when DRC is used. Modified from 
Funder et al: The Management of Primary Aldosteronism: Case Detection, Diagnosis and Treatment: An 
Endocrine Society Clinical Practice Guideline, JCEM 2016, 101(5): 1889-1916 
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Cut-off values for positive ARR depend on the assay. Renin may be measured as 
direct renin concentration (DRC), or as the intrinsic angiotensin I formation capacity 
of plasma renin, termed plasma renin activity (PRA). Accurate and highly 
reproducible assays of both renin and aldosterone are essential for reliable ARR 
results and all further stages of the diagnostic workup. Concern has been raised about 
the reliability and reproducibility of current available automated chemiluminescence 
immunoassays for aldosterone and DRC, which have replaced the more laborious 
aldosterone and PRA radioimmunoassays (10, 147). The development of new, highly 
reliable liquid chromatography tandem mass spectrometry (LC-MS/MS) 
methodology for aldosterone and recently for PRA represents a major step forward 
(148, 149). Furthermore, methods to measure aldosterone and renin in the same 
sample to simplify the screening procedure are in development (139). 
1.9.2 Confirmatory testing 
When ARR is positive, a confirmatory test should be performed to ascertain or 
exclude a diagnosis of PA. A confirmatory test should, if PA is present, demonstrate 
evidence of ongoing aldosterone production in the face of suppressed renin. Four 
different procedures are in use: saline infusion test (SIT), fludrocortisone suppression 
test, captopril challenge test and oral sodium loading. There is insufficient evidence 
to recommend one test over the others (150, 151). In Norway and in Europe SIT is 
mostly used. Here, two liters of 0.9% saline is infused intravenously over four hours, 
with the patient recumbent from one hour before and during the whole test.  Under 
normal circumstances the saline volume load should suppress the RAAS. 
Inadequately suppressed post-infusion aldosterone value confirms PA. Again, 
medication interfering on the RAAS-system should, if considered safe, be withdrawn 
and exchanged with non-interfering medication (Figure 1). The optimal cut-off value 
for a positive SIT post-infusion aldosterone level, representing the best trade-off 
between sensitivity and specificity is still debatable, but 140 pmol/L is commonly 
used (139, 152, 153). Two additional modified confirmatory tests were recently 
proposed; a dexamethasone-enhanced fludrocortisone suppression test, eliminating 
the effect of stress-induced ACTH on aldosterone secretion, found a very high 
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prevalence of PA of 31% (154). Similarly, a seated SIT was shown to be more 
sensitive than the recumbent SIT (155).  
In the setting of spontaneous hypokalaemia, plasma renin below detection level and 
aldosterone levels above 550 pmol/L no further confirmatory testing is needed (139). 
1.9.3 Subtype testing 
When PA is confirmed, all patients should undergo adrenal computed tomography 
(CT) to exclude adrenal carcinoma and to assist the interventional radiologist and 
surgeon in the event of future adrenal surgery. However, for subtype evaluation 
adrenal CT has several limitations. The visualised adenomas may be non-secreting, 
and small secretory adenomas may be overseen or misinterpreted as nodular 
hyperplasia, or nodular hyperplasia may be misinterpreted as several small APAs.  
Several studies have shown low sensitivity and specificity of CT when compared 
with adrenal vein sampling (AVS, see below); concordance rates between CT and 
AVS vary from 40% to 79% (156-159). Therefore, AVS is recommended for subtype 
differentiation in all patients where surgery is feasible and desired, to determine if the 
patient has unilateral PA that will benefit from unilateral adrenalectomy. Only 
patients younger than 35 years with spontaneous hypokalaemia, marked aldosterone 
excess (aldosterone above 831 pmol/L) and with adrenal CT showing a solitary 
unilateral adenoma, may proceed directly to unilateral adrenalectomy without AVS 
(139).  
During AVS (Figure 6), both adrenal veins are approached by percutaneous 
catheterisation of the femoral vein. Blood is then obtained from both the adrenal 
veins and from the inferior vena cava, and analysed for concentrations of cortisol and 
aldosterone. The procedure may be performed with stimulation from the synthetic 
ACTH derivate cosyntropin (Synacthen®). Cosyntropin is given continuously or as 
bolus, to maximise cortisol secretion from both adrenals, to minimise pulsatile or 
stress-induced variations in the secretions of cortisol and aldosterone, and to increase 
aldosterone secretion from an APA (160). If performed without consyntropin, both 
adrenals should be sampled simultaneously and preferably in the morning.  
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Adrenal vein samples are often obtained from near the orifice of the adrenal vein, due 
to difficulties in placing the catheter tip within the small adrenal veins. Dilution from 
non-adrenal vein blood may then occur. To correct for such dilution and to secure the 
adequacy of the cannulation, cortisol is measured simultaneously with aldosterone.  
Adrenal vein cannulation is normally considered successful if the selectivity index 
(SI), i.e. the cortisol gradient of the ratio adrenal vein/inferior vein is above 3-5 with 
cosyntropin, or above 2-3 without cosyntropin. The lateralisation index (LI) is 
defined as the aldosterone/cortisol ratio in one gland compared with the 
aldosterone/cortisol-ratio in the opposite gland. With cosyntropin, a LI above 4 is 
considered to represent lateralisation to one adrenal gland. LI between 3-4 represents 
an overlap zone, whereas a LI below 3 is consistent with bilateral aldosterone 
secretion. Without cosyntropin, a LI above 2-4 is recommended as cut-off for 
lateralisation. No consensus exists about the optimal cosyntropin stimulation 
protocol, and there is no conclusive evidence to recommend cosyntropin stimulation 
to unstimulated AVS (160-163). Moreover, recent studies have shown 9-28% 
disconcordance for lateralisation results when comparing unstimulated with 
stimulated results during the same AVS procedures (164-166). Some centres also 
interpret contralateral suppression, defined as aldosterone/cortisol ratio from the non-
dominant adrenal gland lower than the peripheral aldosterone/cortisol ratio, as an 
Figure 6  Schematic drawing of the AVS 
catheterisation procedure of the left and 
right adrenal veins, with catheters 
introduced via the femoral vein. Monticone 
et.al: Adrenal vein sampling in primary 
aldosteronism: towards a standardised 
protocol, the Lancet Diabetes & 
Endocrinology, volume 3, no 4, p 296-303, 
April 2015. Reprinted with permission. 
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additional criterion for lateralisation. However, no outcome studies show 
unequivocally that contralateral suppression is a useful diagnostic criterion (164, 167, 
168).  
For unstimulated AVS, where the SI may be falsely low, plasma metanephrine, 11-
deoxycortisol, androstenedione and 17-α-hydroxyprogesterone have all been 
suggested as better indicators than cortisol, if cortisol fails to confirm bilateral 
successful cannulation (169-171). 
As for screening and diagnostic testing, withdrawal and replacement of 
antihypertensive agents interfering with the RAAS should also be performed before 
AVS (Table 1). However, in patients with treatment-resistant HT withdrawal of 
several hypertensive agents may not be medically opportune, and angiotensin II-
blockers and ACE-inhibitors may then be used as long as renin is suppressed. With 
low or suppressed renin-levels, it is considered unlikely that these medications will 
stimulate a non-dominant contralateral gland sufficiently to confuse the interpretation 
of the AVS (160). In patients with uncontrolled hypokalaemia and uncontrolled HT, 
even MR antagonists may be continued during AVS as long as renin values remain 
low, without obscuring lateralisation results (172). 
AVS is a technically challenging procedure, especially for the right adrenal vein, 
which is short, small in calibre, may have an angulated path and normally drains 
directly into the inferior vena cava in an acute angle. This makes it difficult both to 
identify, cannulate and withdraw blood samples from (173). The success rates of the 
procedure differ substantially between centres, and increase with the experience of 
the interventional radiologist and by implementing standard operating procedures to 
increase accuracy (156, 174). The introduction of a rapid intraprocedural cortisol 
assays was first reported in 2000, with the first AVS study applying a intraprocedural 
cortisol assay in patients with PA published in 2007 (175, 176). Here, after collecting 
samples from the putative left and right adrenal vein and from the inferior vena cava, 
blood samples are immediately analysed with the intraprocedural cortisol assay, 
either in the laboratory or at point-of-care in the immediate vicinity of the radiologist 
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operating suite. While the analyses are being performed, the catheters are removed 
from the patient, but the catheter sheaths are left in place. The results from the 
intraprocedural cortisol assay ensure feedback within 20-60 minutes of whether the 
adrenal cannulation was successful or not, allowing for immediate resampling of 
improperly collected adrenal samples. A few studies have followed, all showing 
significantly increased AVS success rates when applying intraprocedural cortisol 
assays (177-180). However, all the studies used different AVS study protocols, and 
only in one of those studies cortisol was analysed using a point-of-care instrument 
(175). 
Segmental AVS, in which blood is collected from the intra-adrenal tributaries of the 
adrenal vein instead of from the central adrenal vein, may provide more precise 
localisation of both the intra-adrenal source of aldosterone oversecretion and of 
unaffected adrenal segments. Thus, segmental AVS may be useful in identifying 
patients eligible for adrenal sparing surgery, but requires a highly experienced 
radiologist and is more expensive than standard AVS (181).  
In the event of failed cannulation of an adrenal vein, a recent study found that if the 
aldosterone/cortisol-ratio from the successfully cannulated adrenal vein divided by 
the aldosterone/cortisol ratio from the peripheral vein was below 0.5, this identified 
patients with contralateral unilateral disease (182).  
Complication rate after AVS is low; at centres with experienced radiologists less than 
2.5% (139). In a large study, the rate of adrenal vein rupture was 0.61% (162). 
Adrenal vein hemorrhage may subsequently occur, but normally does not affect 
adrenal function (183). 
As mentioned above, concomitant glucocorticoid secretion may occur in PA (113, 
132). In such cases, concomitant aldosterone and cortisol secretion from an APA 
could confound both confirmation of successful cannulation and interpretation of 
AVS by masking lateralisation. Plasma metanephrine has been suggested to yield 
correct lateralisation ratios when cortisol co-secretion is suspected (184).  
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Even though AVS is considered the gold standard to distinguish between unilateral 
and bilateral forms of PA, it has several limitations, as discussed above. It is a 
technical challenging, invasive procedure which demands dedicated experienced 
radiologists, success rates vary highly, and it has high costs and is not widely 
available in all centres. Furthermore, different protocols are in use at different 
centers, i.e. use of bolus or continuous cosyntropin or none, applying sequential or 
simultaneous cannulations, and criteria for defining successful cannulation and 
lateralisation (139). The stringency of criteria used has been shown to greatly impact 
the reproducibility of AVS results, and different criteria translate into heterogeneous 
classification that influences management decisions (185, 186). In 2016, a large 
prospective randomised multicentre study (the SPARTACUS trial) compared AVS 
with CT-determined treatment outcome. This study showed no significant differences 
in intensity of antihypertensive medication or health-related quality of life after one 
year, challenging the current recommendations that AVS should be performed in all 
PA patients (187). The results from the SPARTACUS trial were met with broad 
interest, but have also triggered extensive discussions and controversies (188).  
11C-metomidate is a positron emission tomography (PET) radiotracer which acts as a 
potent inhibitor of adrenal steroidogenic enzymes. It is selectively accumulated in 
APAs, and 11C-metomidate PET-CT has been shown as a sensitive and specific non-
invasive alternative to AVS for subtype differentiation of PA. Its use is limited by the 
short half-life of 11C-metomidate which requires PET centres with access to an on-
site cyclotron (189, 190).   
The potential roles of serum and urine measurements of the aldosterone precursor 18-
hydroxycorticosterone (Figure 1), and the hybrid steroids 18-hydroxycortisol and 18-
oxocortisol, have also been evaluated in the diagnosis and subtyping of PA. Levels of 
18-hydroxycortisol and 18-oxocortisol are extremely low in healthy individuals, but 
are greatly elevated and particularly valuable in the diagnosis of GRA (191). Several 
studies have shown that these steroid assays are also elevated in non-familiar PA, in 
particular in APAs, and may therefore contribute in both diagnostic workup and 
subtype differentiation of PA (192-197).    
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1.10 Treatment of PA 
PA can be targeted with specific treatments and is potentially curable in unilateral 
cases. Unilateral laparoscopic adrenalectomy is the recommended treatment in 
patients with unilateral PA. Lifelong medical treatment with MR antagonists is 
recommended in bilateral disease or in unilateral disease if surgery is not feasible or 
desired (139).   
1.10.1 Surgical treatment 
Laparoscopic surgery is the gold standard for adrenal surgery due to its low morbidity 
and short hospital stay (198, 199). It can be performed with transperitoneal or 
retroperitoneal approach, and total adrenalectomy is normally performed (Figure 7). 
Partial adrenalectomy is an alternative. However, a patient with unilateral PA may 
have multiple adjacent nodules, with unknown source of aldosterone oversecretion, 
and HT may therefore persist after partial adrenalectomy (200). The mean operative 
time was 2-3 hours in a series of high-volume referral centres, with a 3.4% 
conversion rate to open surgery, and an overall mortality rate of 0.4% (201) . In a 
systematic review, the mean complication rate was 4.7% (202). Bleeding is the most 
frequent severe complication of laparoscopic adrenalectomy. Patients are observed in 
hospital for about three days, with BP and potassium levels monitored. Potassium 
supplements and MR antagonists are withdrawn immediately postoperatively, other 
antihypertensive therapy is reduced when appropriate. A generous sodium diet during 
the first weeks after surgery should be recommended, to avoid hyperkalaemia that 
may develop from hypoaldosteronism due to chronic suppression of the contralateral 
adrenal gland (139, 203). A recent consensus document recommends that a post-
surgical assessment of BP and potassium level should be performed within the first  
three months, whereas final outcome including BP, potassium, aldosterone and renin 




The published cure rates of HT after unilateral adrenalectomy vary widely, from 20-
70% of PA patients in different reports, albeit with significant improvement of HT 
and resolution of hypokalaemia in the remainder (157, 202, 204-211). Factors 
associated with cure of HT are lack of family history of HT, preoperative use of only 
two or fewer antihypertensive drugs, short duration of HT, high preoperative urinary 
aldosterone levels, young age, female sex and no sign of LV hypertrophy (204, 209, 
210, 212-214). Histopathological examinations of resected adrenals show a single 
adenoma in 43-77% of the cases, and multinodular or diffuse hyperplasia in the 
remaining. Some, but not all studies have found an association between a 
histopathological single adenoma and cure of HT (62, 210, 215, 216).  
Development of postoperative hypoaldosteronism with hyperkalaemia due to chronic 
ZG suppression in the remaining adrenal gland has been reported in 5% of 
adrenalectomised PA patients, and may require long-term fludrocortisone 
replacement treatment (203). In the study described above, where increased urinary 
cortisol output in PA was found, 29% of the patients demonstrated an inappropriately 
low response to cosyntropin stimulation post-adrenalectomy, indicative of a 
compromised cortisol reserve. Thus, adrenal insufficiency postoperatively may occur 
more frequently than previously thought (113).    
Biochemical cure after adrenalectomy is indicated by resolution of hypokalaemia and 
normalisation of the ARR. A post-adrenalectomy confirmatory test may also be 
Figure 7 Resected adrenal with a 
single adenoma from a 57-year old 
female PA patient with AVS-
lateralisation (courtesy of endocrine 
surgeon Anette Heie). 
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performed, at least in the event of persistent elevated ARR. Biochemical cure rates 
vary in the range 83-100% (204).   
1.10.2 Medical treatment 
In patients with bilateral PA, lifelong treatment with a MR antagonist that inhibits 
aldosterone-induced activation of the MR, is recommended. Spironolactone, 
developed in the late 1950s, is the drug of choice, with a recommended starting dose 
at 12.5 to 25 mg daily in a single dose, and a maximum dose 100 mg per day (139, 
217-219). However, spironolactone is an unselective MR antagonist that also binds to 
the androgen and progesterone receptors, where it acts as an androgen antagonist and 
progesterone agonist. It may therefore cause adverse effects such as impotence, 
gynaecomastia, mastodynia and menstrual abnormalities (220). Eplerenone, released 
in 1987, is a more selective MR antagonist with fewer side effects (221). It has only 
50% of the MR antagonist potency of spironolactone and a shorter half-life, and 
should be given twice daily, with a recommended starting dose at 25 mg x 2. Both 
spironolactone and eplerenone efficiently reduce BP in PA, but spironolactone may 
have an antihypertensive effect superior to eplerenone (220).  
Agents acting by blocking the epithelial sodium channels of the distal tubuli (e.g. 
amiloride) are also beneficial in reducing HT and ameliorating hypokalaemia in PA, 
but are not recommended as monotherapy as they do not prevent the deleterious 
effects of aldosterone excess in other organs.    
Many PA patients require supplemental antihypertensive agents used in combination 
with MR antagonists to lower BP adequately. Little evidence exists to favour one 
class of agents over other, but ACE inhibitors, angiotensin II receptor blockers, 
calcium channel antagonists and thiazide diuretics are all commonly used in PA (10, 
139). 
Spontaneous remission of IHA after long-term medical MR antagonist treatment has 
been reported (222, 223). It has been postulated that this remission may be caused by 
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reduced vascular and adrenal sensitivity to angiotensin II, or that spironolactone may 
exert a direct inhibitory action on adrenal steroidogenesis (224).   
In carefully selected patients with bilateral PA, unilateral adrenalectomy may be 
beneficial if medical therapy has failed because of intolerance or inadequate BP 
response (225).  
1.10.3 Sodium restriction 
In patients with bilateral PA, due to the deleterious combined effects of high 
aldosterone levels and an inappropriate sodium status, dietary sodium restriction 
should be recommended (15).  
1.10.4 New approaches to medical treatment 
A new class of non-steroidal MR antagonists was recently discovered, which exhibits 
similar in vitro potency to spironolactone, but without effects on androgen and 
progesterone receptors (226, 227). These drugs, termed third-generation MR 
antagonists, are now tested on other patient groups, and may be available for use in 
PA in a few years. Another attractive option would be drugs that could inhibit 
aldosterone synthase. The current recommended treatment for PA with MR 
antagonists activates the RAAS, which leads to high levels of aldosterone that may 
overcome the MR blockade, requiring escalation of doses. In addition, increased 
aldosterone levels may be responsible for non-genomic aldosterone effects (228, 
229). Therefore, selective aldosterone synthase inhibitors are eagerly anticipated. 
1.11 Effects of treatment on organ damage 
In addition to the antihypertensive effect seen both after adrenalectomy and after 
medical treatment with MR antagonists, specific PA treatment also causes beneficial 
effects on cardiovascular and renal outcomes.  
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1.11.1 Cardiovascular outcomes 
Spironolactone treatment was first shown to reduce both morbidity and mortality 
when added to standard therapy among patients with severe heart failure in the large 
RALES trial in 1999. The EPHESUS trial in 2001 showed a similar beneficial effect 
on morbidity and mortality with the addition of eplerenone to optimal medical 
therapy in patients with acute myocardial infarction and heart failure (230, 231). In 
PA, several echocardiographic long-term follow-up studies have shown significant 
decrease in LV mass following both adrenalectomy and MR antagonist treatment. 
The reduction in LV mass seems to occur earlier after adrenalectomy than in those 
treated medically (75, 207). However, in a CMR study of PA patients treated with 
MR antagonists, significant decreases in both LV mass and LV end-diastolic volumes 
were found already after three months (232). A meta-analysis of echocardiographic 
studies found that the reduction in LV mass was similar after adrenalectomy as after 
medical MR antagonist treatment, although BP reduction was greater after 
adrenalectomy (233). Furthermore, the increased risk of cardiovascular events found 
in PA at diagnosis, aligns with that of essential HT at long-term follow-up after 
specific PA treatment (83, 207). However, a recent large retrospective longitudinal 
study found that PA patients treated with MR antagonists had higher incidence of 
cardiovascular events and death than patients with essential HT (234). The higher risk 
appeared to be limited to PA patients whose renin activity levels remained suppressed 
on MR antagonist therapy. Achieving non-suppressed renin levels, either by 
increasing MR antagonist dose or by lowering sodium intake (235), may therefore be 
a treatment target to reduce cardiovascular risk. In contrast, patients with surgical 
treated PA had lower risk of incident cardiovascular events than in essential HT. To 
our knowledge, no CMR studies have been published evaluating cardiac fibrosis after 
treatment of PA.   
In low-renin HT, MR antagonist treatment has been shown to be equally effective as 
in PA, both in reducing BP and LV hypertrophy (236).  
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1.11.2 Renal outcomes 
Improvement of albuminuria is also seen after specific PA treatment, but also a fall in 
glomerular filtration rate (GFR). These findings indicate that renal dysfunction in PA 
is characterised by reversible glomerular hyperfiltration, with elevated albuminuria 
being a marker of a dynamic rather than structural renal defect (102, 103).  
1.11.3 Metabolic outcomes 
Data on effects on glucose metabolism after PA treatment are sparse. In one study, 
insulin resistance was restored to normal after adrenalectomy and MR antagonist 
treatment. In another study, first phase insulin reaction in intravenously glucose 
tolerance test increased significantly after adrenalectomy (110, 237). In a recent large 
national health insurance database study, PA patients who underwent adrenalectomy 
had a reduced risk of diabetes mellitus compared with essential HT, whereas PA 
patients treated with MR antagonists were at increased risk. This difference may be 
caused by high circulating levels of aldosterone in MR antagonist treated patients, 
causing non-genomic deleterious effects including insulin resistance (238). However, 
it has also been postulated that concurrent glucocorticoid excess found in PA, 
removed by adrenalectomy but remaining unopposed by MR antagonist treatment, 
may be the main cause of increased metabolic risk in the latter group (239). The same 
hypothesis may apply to the long-term increased rate of osteoporotic fracture risk 
found in female PA patients treated with MR antagonists, but not after adrenalectomy 
(124). 
1.11.4 Effect of treatment on quality of life 
Quality of life improves after specific PA treatment (128, 129). In a recent 
prospective study, a larger improvement in quality of life was seen after 
adrenalectomy than in patients treated medically with MR antagonists (130).  
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1.11.5 Effect of treatment on mortality  
Recently, reduced long-term all-cause mortality after adrenalectomy was 
demonstrated, as compared with patients treated with MR antagonists and patients 
with essential HT. For MR antagonist treated PA, a defined daily dose of 12.5-50 mg 
spironolactone was associated with lower mortality compared with lower or higher 
doses (238, 240).  
1.12 Summary 
To summarise, based on epidemiological studies, PA is still grossly underdiagnosed 
in most countries, probably also in Norway (29, 31). However, no studies of PA in 
Norway had been published at the start of this PhD work in 2013.  Based on evidence 
described above, both surgery and medical treatment with MR antagonists efficiently 
decrease the excess organ complications found in untreated PA. However, recent 
evidence suggests superior effect of adrenalectomy compared with MR antagonist 
treatment both on BP reduction, diabetes, fracture risk, quality of life and mortality. 
These findings emphasise the need for correct diagnosis and subtyping. AVS is the 
gold-standard for subtyping and treatment decision, but is a technical challenging 
procedure with varying success rates without the aid of intraprocedural cortisol 
assays. The increased cardiovascular risk in untreated PA may partly be due to 
myocardial fibrosis. CMR is the recommended imaging modality for myocardial 
tissue characterisation, and new CMR T1 mapping techniques enable quantitative 
assessment of diffuse myocardial fibrosis. However, to our knowledge, no studies 
applying CMR T1 mapping techniques have been performed in human PA, and the 
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2 Aims 
Overall objective  
 To determine the clinical and biochemical characteristics of the PA population 
in Western Norway, identify the optimal diagnostic procedures and evaluate 
the long-term treatment outcome after surgical and medical treatment. 
 
Specific aims 
 Describe the epidemiology and patient characteristics, diagnostic approach, 
somatic mutational status and long-term treatment-outcome of PA in Western 
Norway (paper I).  
 
 Determine the success rate of AVS using intraprocedural point-of-care cortisol 
analysis (paper II).  
 
 Apply cardiac magnetic resonance imaging to assess myocardial mass, function 








3 Materials and methods 
The work is based on three clinical studies all conducted at the tertiary centre 
Haukeland University Hospital in Bergen, Norway. Haukeland University Hospital is 
one of only two university centres in Norway that perform AVS. It therefore serves as 
a tertiary referral centre for all PA patients admitted for subtype testing from the 
Western and Middle parts of Norway, and to some extent also for the Northern parts 
of the country.   
3.1 Study design and patients 
Paper I 
In this study, all patients who had been investigated for PA during the period 1998-
2012 at Haukeland University Hospital were retrospectively evaluated. AVS was 
introduced at Haukeland University Hospital in 1998, representing the starting point 
of recommended subtyping of our PA patients. Inclusion criteria were verified PA 
after confirmatory testing, or highly likely PA including elevated ARR and severe or 
treatment resistant HT with or without hypokalaemia. Clinical characteristics, 
diagnostic work-up and treatment were retrieved from patient records. Adrenal 
imaging and histological slides of adrenal tissue were reevaluated, and analysed for 
somatic mutations in genes known to cause PA. All patients still alive by August 
2014 were invited to a follow-up visit at our out-patient clinic, for evaluation of 
clinical and biochemical outcome.  
Paper II 
Here we compared AVS results performed with and without the use of 
intraprocedural point-of-care cortisol assay. Twenty-one consecutive patients with 
confirmed or a strong suspicion of PA who were planned for AVS were included.  
Their AVS were performed in the period February-April 2013, applying 
intraprocedural point-of-care cortisol assay during the AVS procedure. Interfering 
antihypertensive medication was changed 2-4 weeks before the procedure, according 
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to guidelines, if considered safe. The previous 21 AVS procedures without the use of 
intraprocedural cortisol assay were used as controls.  
Paper III 
This study assessed cardiac mass and fibrosis in PA before and after specific PA 
treatment, compared with normotensive healthy subjects, applying CMR. In the 
period October 2013-June 2014, fifteen patients with newly confirmed PA (PA1) and 
24 age-and sex-matched healthy subjects were included for baseline CMR 
examinations, performed with dynamic contrast enhancement (CMR1-C1). Then, at 
least one year after start of specific treatment, both the PA1 group and the healthy 
subjects were invited to a follow-up CMR with T1 mapping technology (CMR2-T1), 
which had replaced the original CMR scanner used at baseline. In order to obtain T1 
mapping also from a group of newly diagnosed PA, an additional 17 patients with 
newly confirmed PA (PA2) were recruited, of whom 16 were included in the study.  
The CMR2-T1 sub-study was performed between June 2015 and March 2016. A 
study flow chart for the different study groups participating in CMR1-CI and CMR2-
T1 is shown in Figure 7.  
 
Figure 7 Study flow chart for the three study groups in Paper III; PA1, HS and PA2. Abbreviations: 
PA1, primary aldosteronism group 1; HS, healthy subjects; PA2, primary aldosteronism group 2; CMR1-CE, 
cardiac magnetic resonance imaging with dynamic contrast enhancement; CMR2-T1, cardiac magnetic 
resonance imaging with T1 mapping 
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3.2 Laboratory assays for aldosterone, renin and cortisol 
Hormone measurements for case detection and diagnostic testing in regional PA 
patients, and all hormone measurements performed during AVS procedures, were 
analysed at the Hormone Laboratory of Haukeland University Hospital. The assays 
for both aldosterone and renin were changed during the study period of Paper III, 
with replacement of plasma renin activity (PRA) with direct renin concentration 
(DRC).  
From the1990s until December 2014, plasma aldosterone was measured using the 
radioimmunoassay Coat-a-Count® Aldosterone (Siemens) (Paper I, II and III). The 
aldosterone assay was in December 2014 replaced with the chemiluminescent 
immunoassay LIAISON® Aldosterone (DiaSorin) (Paper III). Aldosterone was 
measured as pmol/L with both methods. The normal reference range was modified 
from 110-860 pmol/L in the first assay, to 70-1086 pmol/L in the new assay (upright 
position).   
From the 1990s until February 2016, renin was analysed as PRA, using the 
radioimmunoassay Gammacoat® (DiaSorin), given as µg/L/t (Paper I, II and III). 
From February 2016 onwards, the assay was replaced with the chemiluminescent 
immunoassay LIAISON® Direct Renin (DiaSorin) measuring DRC, given as mIE/L 
(Paper III). 
For the ARR, a value above 750 pmol/µg/h was considered elevated with renin 
measured as PRA (Paper I, II and III) (138). For ARR calculated with DRC, the cut-
off value depended on whether aldosterone was below or above 300 pmol/L. With 
aldosterone below 300 pmol/L an ARR above 50 pmol/mIE was considered elevated, 
whereas for aldosterone above 300 pmol/L, the cut-off for elevated ARR was set at 
35 pmol/mIE (Paper III).  
Cortisol was until February 2003 measured using AutoDELFIA® automatic 
immunoassay system (PerkinElmer life sciences) (Paper I). From February 2003 
until May 2013 cortisol was analysed using the automated immunoassay IMMULITE 
 49 
2000 (Siemens) (Paper I and II).  For Paper II, cortisol was also analysed with an 
inhouse LS-MS/MS assay. From May 2013 onwards, cortisol was measured using 
this LS-MS/MS assay (Paper III).  
Intraprocedural cortisol (Paper II) was analysed at point-of-care using the AIA-360 
Cort-pac system (TOSOH Bioscence). Lithium/heparin tubes were centrifuged 
immediately, and the samples were then analyses for cortisol undiluted and at 1/20 
and 1/39 dilution. The first results were available 20 minutes after the samples were 
loaded into the analyser, with further samples analysed every 1.5 minutes. With 
sample centrifugation and dilution included, results were available 25-30 minutes 
after the samples were obtained.  
3.3 Confirmatory testing 
Recumbent saline infusion test (SIT) was the confirmatory test in use at Haukeland 
University Hospital. The patients stayed recumbent for one hour before and during 
the infusion of two liters of 0.9% saline given intravenously over four hours. Blood 
samples were drawn before and at the end of the infusion. A positive SIT was defined 
as a post-infusion plasma aldosterone level above140 pmol/L (Paper I, II and III) 
(138, 152).  
In cases where patients were admitted from other Norwegian hospitals with the 
captopril challenge test used as confirmatory test, an aldosterone suppression of less 
than 30% of baseline values was considered positive (Paper I) (138).  
3.4 Adrenal vein sampling 
All AVS procedures (Paper I, II and III) were performed within the Department of 
Radiology at Haukeland University Hospital, and were performed with sequential 
cannulation of both adrenal veins during continuous cosyntropin (Synacthen®) 
infusion 50 µg/h, by dedicated radiologists. Samples were collected from the putative 
left and right adrenal vein and from the inferior vena cava.  
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For Paper II, blood samples were immediately analysed with the intraprocedural 
point-of-care cortisol assay, situated in the room next to the radiologist operating 
suite. While the analyses were performed, the patient remained in the radiology suite, 
and the catheter sheaths were left in place until the results of the intraprocedural 
cortisol assay were available. If these results indicated incorrect catheter position 
from one or both adrenals, a new attempt of cannulation of the adrenal vein was 
performed, with repeated samples drawn. 
The cut-off for correct catheter position (selectivity index) was defined as a ratio of 
adrenal vein cortisol to peripheral cortisol level above 5. A lateralisation index 
(aldosterone/cortisol-ratio from dominant to contralateral adrenal vein) above 4 was 
defined as cut-off for unilateral PA (156, 161).  
3.5 Adrenal imaging 
For Paper I, all CT and MRI examinations were re-evaluated by an experienced 
radiologist. Axial scans (3 mm) were used for evaluation of both modalities. Normal 
adrenals were classified as a limb junction less than 8 mm and both limbs less than 5 
mm. Hyperplasia was defined as the junction and limbs equal to or exceeding 8 and 5 
mm. Macronodular hyperplasia was defined as hyperplasia with one or more nodules, 
and a tumour was defined as a focal lesion exceeding 10 mm in diameter (241). 
3.6 Histopathology and genetic analysis  
In order to obtain a uniform histopathological evaluation, all available original 
histological slides and biopsy reports for Paper I were reviewed by one pathologist. 
Microscopically, the specimens were classified as histopathological normal tissue, 
adenoma(s), hyperplasia with or without macronodules, or uncertain.  
For molecular genetic analysis, one block from each nodular lesion or from the most 
nodular area, and an additional block from normal adrenal tissue were selected for 
molecular genetic analysis. From 2009 onwards, tissue samples for genetic analysis 
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were collected directly after adrenalectomy from both macroscopic tumour tissue or, 
when no tumour was present, from the most thickened area of the adrenal cortex, and 
from macroscopically unaffected adrenal gland, and stored at -80°.  
Genomic DNA was extracted from shaves of archived formalin-fixed paraffin-
embedded tissue, or isolated from fresh tumour and non-tumour tissue, using 
QIAamp DNA FFPE Tissue Kit, according to the manufacturer`s instruction. DNA 
regions where mutations in the genes KCNJ5, ATP1A1, ATP2B3, CACNAID and 
CTNNB1 had previously been identified were amplified by PCR using gene-specific 
primers. No patients were tested for germline mutations.  
3.7 Clinical follow-up 
All patients included in Paper I who were still alive by 2014, were invited to a 
clinical follow-up at the outpatient clinic of Haukeland University Hospital to assess 
clinical and biochemical outcome. In order to get a correct measure of their BP 
outcome, the patients were asked not to stop or change interfering antihypertensive 
medication prior to the visit. BP was measured manually in a standardised manner, 
with the patient having being seated for at least five minutes, with three repetitive 
measurements, using the mean of the second and third measurement. Blood samples 
were drawn between 8.30 a.m. and noon, with the patient in the seated position for 
the last five minutes. Cure of HT was defined as BP below140/90 without the aid of 
antihypertensive medication. Improved HT was defined as the same or reduced BP 
compared with baseline, and decrease of at least one antihypertensive medication. 
Persistent HT was defined as unchanged or increased BP with either the same or 
increase in antihypertensive medication. Biochemical cure after adrenalectomy was 
defined as ARR below 750 pmol/µg/h.  
Medically treated patients who had not had AVS or had a non-representative AVS, 
were offered a new AVS with intraprocedural cortisol analysis.  
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3.8 Cardiac magnetic resonance imaging and analysis 
In Paper III, the baseline sub-study of CMR with dynamic contrast enhancement 
(CMR1-CE) was performed with a 3T GE Signa Excite scanner (Milwaukee, WI, 
USA). This scanner was replaced in June 2014 with a 3T Siemens Magnetom Skyra 
(Erlangen, Germany) with T1 mapping technology, which was used for the T1 
mapping sub-study (CMR2-T1).  
For both scanners, images were obtained during breath-hold with ECG-triggering. LV 
mass, volumes and function were analysed from short-axis CINE views, with manual 
tracing of endo-and epicardial borders in all slices in end-diastole and end-systole, 
excluding papillary muscles. The software Segment, version 1.9 R3697 was used to 
calculate values for LV mass, end-diastolic volume, end-systolic volume, stroke 
volume, cardiac output and ejection fraction, and the values were indexed to body 
surface area.  
All post-image analyses were performed by two different investigators, and the mean 
of their results was applied for statistical analyses.  
Estimation of dynamic contrast enhancement 
For the contrast enhancement image acquisition in CMR1-CE, a protocol earlier 
published by Su et al. was adopted and slightly modified (99). Mid-ventricular short 
axis views were obtained before and 2,4,6,8,10,12 and 14 minutes after 
administration of 0.2 mmol/kg body weight of a gadolinium based contrast agent 
(Gadovist 1 mmol/mL). Three non-overlapping regions of interest (ROI) were placed 
both in the interventricular septum and within the LV lumen from pre- and post-
contrast images, and the average signal intensities (SI) both from the interventricular 
septum and lumen were calculated. Adopted from Su et al, contrast enhancement 








SI post.contrast myo = the signal intensity (SI) of myocardium after contrast, SI native myo = the SI of 
myocardium before contrast, SI post.contrast blood = SI within the lumen after contrast, and SI native blood = 
SI within the lumen before contrast 
Estimation of myocardial fibrosis from T1 mapping 
For the T1 mapping images in CMR2-T1, an inversion recovery based MOLLI 
sequence was used. A pre-contrast T1 mapping mid-ventricular short-axis view was 
performed before administration of Gadovist 0.15 mmol/kg body weight. Further T1 
mapping images were then performed at 10, 15 and 20 minutes post-contrast. The 
syngo.via software (Siemens, Erlangen) was applied for T1 mapping calculations. A 
ROI covering most of the interventricular septum and one ROI within the LV lumen 
were drawn from pre- and post-contrast T1 mapping views. Following a recent 
consensus statement by the Society for Cardiovascular Magnetic Resonance, the 
extracellular volume (ECV) % was calculated as a surrogate marker for the 
extracellular space using the following formula (95):  












 x (100 – haematocrit) 
T1 post.contrast myo = SI of myocardium after contrast, T1 native myo = SI of myocardium before contrast, T1 
post.contrast blood = SI within the LV lumen after contrast, and T1 native blood = SI within the lumen before 
contrast. 
3.9 Statistical analysis 
All parameters were expressed as median and ranges. Student’s t-test and Mann-
Whitney U-test were used to compare normally and non-normally distributed 
continuous data between two groups, and Wilcoxon Signed Rank Test for within-
group not normally distributed data. The Chi-square test or Fisher`s Exact 
Probability test were used as appropriate for comparison of categorical data. Trend 
lines for biochemical correlations in Paper II were fitted using linear regression. In 
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Paper III, one-way ANOVA was used to compare continuous data between three 
groups, and Bland-Altman plots were used to analyse the agreement between 
measurements performed by two investigators. For all statistical tests, a p-value less 
than 0.05 was considered statistically significant.  
3.10 Ethics 
All studies were approved by the Regional committee for medical and health research 
ethics for Western Norway (2012/1702, 2012/1856 and 2013/742). Written informed 
consent was in study I obtained from all adrenalectomised patients and from all 
patients still alive who met to follow-up in 2014. In study II and III written consent 
was obtained from all patients.  
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4 Results  
4.1 Paper I 
We retrospectively identified 108 patients (73 males and 35 females) with a 
confirmed or highly suspected PA, admitted to Haukeland University hospital in the 
period 1998-2012. The included patients had a median 10 year history of HT before 
their diagnosis. A very large proportion (92/108) had a history of hypokalaemia. We 
found that PA had been verified by confirmatory testing in 83/108 of these patients. 
Confirmatory testing had been performed in a higher proportion of the patients after 
publication of clinical guidelines in 2008. The majority of our cohort, 95/108, had 
performed AVS as subtype testing. AVS was representative in 70/95, with unilateral 
PA found in the majority (50/70). However, the proportion with bilateral PA 
increased over the study period. The patients with AVS-confirmed unilateral PA had 
lower serum potassium and higher post-SIT aldosterone levels compared with those 
with bilateral PA.  
Comparison of AVS results with adrenal imaging showed low concordance; only 
27/65 had concordant results on adrenal imaging and AVS. Even in the age subgroup 
35- 40 years, one patient with an adrenal adenoma found by CT imaging had AVS 
lateralisation to the opposite adrenal.  
Sixty-eight of the 108 patients were adrenalectomised, of whom 48 had AVS-
confirmed lateralisation. The remaining patients were operated based on CT/MRI 
imaging, either alone (n=8) or with non-representative AVS results (n=12). Forty 
patients were medically treated, twenty of these had bilateral PA confirmed with 
AVS.  
Sixty-five pathology specimens of adrenal tissue were available for histopathological 
evaluation. Forty-seven of these specimens were defined adenomas, and the 
remaining hyperplasia. KCNJ5 mutational status could be determined in 64 
specimens, with mutations in KCNJ5 found in 19. In two patients, KCNJ5 mutations 
were found in one nodule only of nodular hyperplasia. KCNJ5 mutations were 
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associated with female sex, a florid PA phenotype and a higher cure-rate of HT than 
patients without KCNJ5 mutations. Due to old age and low quality of some of the 
adrenal specimens, only 26/65 specimens were adequate for analysis of the ATP1A1, 
ATP2B3 and CACNAID genes. Of the tested specimens pathogenetic mutations in 
ATP1A1 were detected in 4/39 specimens, all adenomas. Mutations in ATP2B3 (2/39) 
and CACNAID (4/39) were found both in adenomas and nodular hyperplasia. Sixteen 
specimens were analysed for CTNNBI, all tested negative.  
Seventy-three patients met to a clinical follow-up visit in 2014, fifty-two 
adrenalectomised and 21 medically treated. Twelve patients were deceased. Of the 
remaining 23 alive patients who did not meet, fifteen declined the invitation, and the 
remaining patients were unavailable or unable to meet. We found similar BP 
reductions in the adrenalectomised and medically treated patients, but the former used 
fewer antihypertensive drugs and had higher potassium levels; all were 
normokalaemic without potassium supplements after adrenalectomy. Cure of HT 
after adrenalectomy was achieved in 11/52. Female sex, presence of KCNJ5 mutation 
and a histopathological adenoma were associated with cure of HT. Eight of 48 
adrenalectomised patients with available ARR results had persistently elevated ARR 
consistent with no biochemically cure, all with AVS-confirmed lateralisation before 
adrenalectomy. Seven of these had a pathology specimen available, of which four 
showed a histopathological adenoma, the remaining hyperplasia.  
Only 16/21 medically treated patients used MR antagonists at follow-up. All 
medically treated patients without representative AVS results were offered a repeat 
AVS with intraprocedural cortisol analysis. Three of nine patients who accepted were 
later diagnosed with AVS-lateralisation, and were subsequently adrenalectomised.    
4.2 Paper II 
Here we demonstrated that intraprocedural point-of-care cortisol assay increased the 
AVS success rate from 10/21 patients in a historical cohort, to 17/21 patients in the 
study group. The increased success rate was due to a significant increase in 
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representative samplings from the right adrenal vein. In the study group, 13/21 AVS 
procedures were bilaterally representative after the first samples, whereas four 
patients achieved representative samples after a first resampling. Seven of the PA 
patients in the study group had previously undergone an unsuccessful AVS, 
compared with three in the historical cohort. Throughout the study period the success 
rate of representative first set of samples increased, without the need of repeated 
samples. Thirteen of the successful 17 samples in the study group showed AVS-
lateralisation, whereas 6/10 successful samples in the historical cohort lateralised.  
During the study period, the mean time from the patients arrived at the radiology 
suite until the first set of samples was drawn was 88 minutes. The first point-of-care 
cortisol results were available 25-30 minutes after the samples were obtained. Mean 
duration for the whole AVS procedure was 138 minutes.  
The intraprocedural point-of-care cortisol assay showed satisfactory quality compared 
with the routine immunological assay.  
One patient in the study group experienced adverse effects with persistent abdominal 
pain and was readmitted to hospital. CT revealed a small amount of fluid around a 
diffusely oedematous right adrenal gland, treated conservatively without sequelae. 
4.3 Paper III 
In this CMR study we reported the results of both LV mass and fibrosis assessment in 
PA, determined before and after specific treatment. In paper III we found that LV 
mass index in the PA1 group was significantly higher than in healthy subjects at 
baseline, but decreased rapidly after specific PA treatment, with a median of 18 
months since adrenalectomy or start of medical treatment with MR antagonists. The 
decrease in LV mass appeared despite only small non-significant reductions in BP. 
When the adrenalectomised (n=8) and MR antagonist treated (n= 6) PA1 patients 
were analysed separately, the adrenalectomised patients displayed a larger, highly 
significant reduction in LV mass index, whereas the medically treated patient showed 
a trend towards, but no significant reduction in LV mass index.   
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No evidence of myocardial fibrosis in PA was found in the newly diagnosed PA1 
group when measured with CMR with dynamic contrast enhancement (CMR1-CE) 
from 2 to 14 minutes post-contrast, and compared with healthy subjects. Similarly, 
subsequent T1 mapping results from the CMR2-T1 scanner showed no increase in 
ECV as a surrogate marker of interstitial fibrosis in either PA1 (now treated) or the 
PA2 group (newly diagnosed), compared with healthy subjects. On the contrary, 
slightly lower ECV values were found in the newly diagnosed PA2 than in controls at 
both 10 and 20 minutes post-contrast, and in the treated PA1 at 20 minutes post-
contrast.   
Left ventricular end-diastolic index (LV-EDV) showed a non-significant trend of 
reduction after specific treatment (PA1 group). When comparing the 
adrenalectomised with MR antagonist treated patients, a significant reduction in LV-





5  General discussion 
Over the past few decades PA has become recognised as the most common cause of 
secondary HT. The diagnosis may be tricky, but the condition is easily managed and 
potentially curable. PA causes excessive risk of organ complications if not diagnosed 
and treated correctly. Notwithstanding this knowledge, the diagnosis, treatment and 
outcome of the PA population in Norway have not previously been addressed. This 
doctoral thesis is based on researcher initiated clinical studies of the PA population in 
Western Norway, with the overall aim to determine the characteristics of a large 
Norwegian PA population. Specifically, we aimed to evaluate the diagnostic 
procedures in use and treatment outcomes, including effects on the myocardium of 
the disease and its treatment.  
5.1 PA epidemiology and characteristics  
When we first chose to conduct these studies of patients with PA, no scientific 
publication existed on PA patients in Norway. Paper I is a benchmark study, which 
represents a starting point for the evaluation of current practice and for improvement.  
In Paper I, we identified 108 PA patients diagnosed between 1998 and 2012. The 
incidence and prevalence of PA in the population at large are not well known, and are 
mostly given as proportions among selected groups of hypertensive patients.  
Following the revised Endocrine Society guidelines, approximately 50% of patients 
with HT belong to categories at high risk of PA, and should therefore be screened for 
PA (32, 139). In large prospective studies, a PA prevalence at 6% among HT patients 
in primary care and 11% in referred hypertensive patients were found (27, 29). 
However, in a recent survey among primary care physicians in Italy and Germany, 
only 7-8% of patients with HT were screened for PA (242). Similarly, another study, 
also from Italy, showed that only 1.9% of expected patients with PA were diagnosed 
with PA in the period 2000-2015, and 1% of expected adrenalectomies were 
performed (243). In Paper I, presumably all diagnosed PA patients in the three 
counties of Western Norway, harbouring a population of 1.0 million in 2012, 
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underwent diagnostic workup at our centre in the years 1998-2012. If we assume that 
20-30% of the adult population in Norway is diagnosed with HT, the number of 
unidentified PA patients in Western Norway during the study period might have been 
several thousand. We therefore believe that likewise to Italy and Germany, PA is 
grossly underdiagnosed in Norway, with the majority of PA patients never screened 
or diagnosed. Education of both primary care physicians and specialists in referral 
centres to order more ARR testing of their hypertensive patients at risk of PA, should 
be encouraged.  
The diagnosis inevitably depends on diagnostic criteria, i.e. cut-off levels for 
aldosterone and renin levels for screening and diagnostic testing. However, neither 
hormone assays nor recommended cut-of levels are standardised, and large variations 
exist between centres. Additionally, due to circadian variation with primarily 
nocturnal aldosterone hypersecretion, a day-time blood sample may not reflect the 
aldosterone hypersecretion (15). Still, as of today, no other screening test superior to 
ARR exists. Evidence is increasing that a continuum of autonomous aldosterone 
hypersecretion exists beyond the limits of what is today defined as PA, with 
individuals with low-renin HT experiencing a similar beneficial effect of MR 
antagonist treatment as those with IHA. This raises the question as to whether 
distinguishing between PA and non-PA is the most important, or rather only 
diagnosing those with an APA, who should be offered surgical intervention.  
The very high proportions of hypokalaemia and unilateral PA found in our PA cohort 
indicate that mostly PA patients with the more severe phenotypes were diagnosed and 
admitted for AVS. This seems especially evident during the first years of the study 
period, before PA guidelines were published in 2008 (138, 244, 245). However, our 
findings clearly demonstrate that there has been significant development over the 
study period in Norway as elsewhere. One important example is the increased 
proportion of patients undergoing AVS, which increases the precision of the 
subtyping and, consequently, the therapy. Additionally, bilateral PA in our cohort 
increased during the study period, pointing to an increased focus and ability also to 
detect bilateral PA with milder phenotypes. It is likely that the observed increase in 
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incidence reflects increased diagnostic awareness, but true change and regional 
differences due to external factors (lifestyle, environment) cannot be ruled out. 
Like several other PA studies, we found more men than women diagnosed with PA 
(186, 187, 246). However, there are no data showing that PA is more prevalent in 
males than females, and the female dominance in harbouring the  common KCNJ5 
somatic mutation indicates a possible female preponderance in APAs (15). Thus, our 
findings probably reflect a referral bias with an increased attention to diagnose and 
refer male patients for exploration of possible underlying causes of HT. It should be 
remembered that female patients are more likely than men to achieve complete or 
partial clinical success after adrenalectomy (204).  
5.2 Subtype diagnostics 
The principal challenge after the diagnosis is made is to determine whether the 
disease is localised to one side, and thus can be treated with adrenalectomy.   
Adrenal AVS has become the gold standard procedure for detecting lateralisation in 
PA. This recommendation by Endocrine Society Guidelines was based on several 
studies evaluating surgical clinical outcome of surgically confirmed APAs, showing 
that imaging was not reliable compared with AVS in distinguishing unilateral from 
bilateral aldosterone excess (156, 247). However, AVS is expensive, invasive and a 
technical challenging procedure and is only available in specialised centres. Non-
functioning adrenal adenomas are uncommon in younger patients. Therefore, young 
patient below 35 years of age, with spontaneous hypokalaemia, marked aldosterone 
excess and unilateral adrenal adenoma on adrenal imaging may therefore proceed 
directly to adrenalectomy without AVS (139).  
In Paper I, the proportion of patients who underwent AVS increased in the period 
after 2008 compared with the earlier period, pointing towards an increased focus and 
ability to apply AVS for subtyping of PA after the guidelines were published in 2008.   
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In Paper I our results corroborate other studies in that the concordance rate between 
adrenal imaging (CT and MRI scans) and AVS was low. In fact, our concordance 
rates were lower than those found both in a previous systematic review and in a study 
by the Mayo clinic (157, 159).  In this way, we clearly show that AVS has 
contributed to significant improvement in diagnostic quality and, hence, treatment 
safety. Based on abnormal imaging alone, a large proportion of the patients in our 
cohort would either have had the wrong adrenal removed, been unnecessarily 
adrenalectomised, or not been offered adrenalectomy. In accordance with the 
recommendations in the latest Endocrine Society Guidelines, we also found that even 
in the age group 35-40 years, the wrong adrenal would have been removed without 
AVS.  
However, the debate concerning the accuracy of adrenal imaging versus AVS in 
diagnosing unilateral PA has recently been actualised, after the randomised 
SPARTACUS trial showed no difference in BP outcome in patients whose treatments 
decisions were based on CT imaging compared with AVS (187). However, the 
SPARTACUS cohort has been criticised for not being representative of PA. Only 
patients with drug-resistant HT or hypokalaemia, consistent with a severe phenotype, 
and thus less likely to achieve remission of HT, were included. Secondly, the choice 
of daily defined dose of antihypertensive treatment as primary end-point has been 
considered suboptimal, as it does not reflect biochemical cure of PA after 
adrenalectomy. A third area of dispute is the comparison made between AVS versus 
CT-based MR antagonist therapy, since patients with APA also respond well to 
medical therapy. Additionally, the sample size has been criticised for not being 
adequate to prove non-inferiority of CT scanning compared with AVS to determine 
indication for adrenalectomy (188, 248).  
The rate of bilaterally successful AVS found in Paper I was in the middle range 
compared with other reports (156, 174). However, introduction of the intraprocedural 
point-of-care cortisol assay in 2013, as studied in Paper II, showed a significant 
improvement compared with a historical cohort. The increased success rate was 
 63 
caused by an increase in successful cannulation of the right adrenal vein, which, due 
to anatomical reasons it the most difficult to cannulate.   
Interestingly, our study also demonstrated a learning effect for the radiologists, with 
improved successful sampling at first attempt at the end of the study period compared 
with in the beginning. A similar training effect was found in another study (179). 
These findings emphasise the importance of AVS procedures being performed in 
high-volume centres by dedicated, experienced radiologist.   
Including Paper II, several prospective studies have demonstrated increased success 
rates with intraprocedural cortisol assays, independent of different AVS protocols, 
and with low complication rates (175, 177-180). All these studies, including Paper 
II, are referred in the updated Endocrine Society guidelines. However, to this date, no 
randomised trials have been published to conclusively determine if this approach 
improves the success rate of AVS, but a randomised trial  (I-Padua) is now ongoing 
(249). 
PA is associated with significant cardiovascular morbidity. Identification of unilateral 
PA with subsequent adrenalectomy causes greater BP reduction and lowers risk of 
cardiovascular disease compared with medical MR antagonist treatment (233, 234).  
However, the economic costs should be considered before screening procedures and 
subtype diagnostics are implemented to identify patients with surgically correctable 
PA. A cost-effectiveness analysis was therefore performed, which found that CT 
scanning followed by AVS was a cost-effective strategy to identify patient with 
unilateral PA among patients with resistant HT, compared with medical treatment 
alone (250). Still, access to AVS is limited. If far larger groups of patients with PA 
will be diagnosed in the future, this will necessitate new and easier accessible subtype 
diagnostics.  
One such method may be PET-CT. In cases where AVS cannulation is not successful, 
functional imaging with 11C-metomidate PET-CT offers an alternative method of 
subtyping, but the application is limited due to short half-life of the 11C-metomidate 
which requires an on-site cyclotron (189). At our centre we have sent three selected 
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patients with unsuccessful AVS to 11C-metomidate PET-CT (Addenbrooke’s Hospital 
in Cambridge, UK). One of those patients was adrenalectomised based on 11C-
metomidate PET-CT showing lateralisation, with complete biochemical cure. 
However, a molecular tracer with longer half-life than 11C-metomidate and capable of 
binding specifically to aldosterone synthase is desirable (251).  
Another path may be steroid profiling. The development of LC-MS/MS technology 
with simultaneous measurements of multiple steroids in one blood sample including 
the hybrid steroids 18-hydroxycortisol and 18-oxocortisol have shown promising 
results in determining correct subtype in recent retrospective series (194, 197). These 
results need to further be confirmed in prospective studies where steroid profiling 
guides diagnostic decision making.  
5.3  Genetics  
From 2011 onwards, starting with the discovery of the somatic KCNJ5 mutations, the 
genetic basis of APAs has been elucidated. About 60% of APAs in the Western world 
harbour somatic mutations in genes known to be associated with APA (252). In our 
PA cohort in Paper I we found slightly lower frequencies of KCNJ5 mutations than 
reported in two large European multi-centre studies (50, 51). We found the same 
association between mutations in KCNJ5 and female sex as found in those studies 
and in a large meta-analysis (55). Similarly to the meta-analysis, KCNJ5 mutations 
were associated with a more florid phenotype, indicated by higher post-SIT 
aldosterone levels. However, unlike those studies, we found no association between 
KCNJ5 mutations and young age, which could be due to study size.  
Similar to a recent Dutch study, we found somatic KCNJ5 mutations in one nodule of 
nodular hyperplasia in two of 19 patients, as opposed to adenomas in the remaining 
(215). The origin of KCNJ5 mutations is still unknown, but they obviously differ 
from the other somatic mutations. Tumours with KCNJ5 mutations histologically 
display mostly ZF-like cells, in contrast to more ZG-like cells in tumours with other 
somatic mutations. Additionally, KCNJ5 mutations have not been detected in the 
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aldosterone-producing cell clusters APCCs, which may be precursors for some APAs 
and are thought to play a key role in PA development (252, 253).   
Further studies of immunohistochemistry and genetics may elucidate the 
pathophysiology of PA in more detail, which could eventually lead to new diagnostic 
and therapeutic approaches. 
5.4 Treatment outcome  
The ultimate aim of case detection and correct subtyping of PA is to ensure targeted 
treatment depending on whether the PA is unilateral or bilateral, to ensure a best 
possible outcome. Specific PA treatment with either adrenalectomy or MR antagonist 
treatment lowers BP values, lowers cardiovascular, metabolic and renal 
complications, improves quality of life and may biochemically cure unilateral PA, 
compared with non-specific antihypertensive treatment alone (83, 102, 110, 130, 
234). Most likely, the outcomes depend on both the reduction of BP and aldosterone 
levels.  
In our study cohort in Paper I, both HT cure rate (11/52) and biochemical  cure rate 
(8/48) after adrenalectomy were in the low range compared with other reports (157, 
204, 205, 208, 210). The low HT cure rate may have been caused by a relatively 
long-follow up time after adrenalectomy, allowing for age-related coexisting HT. 
Long-standing exposure to excess aldosterone may have caused structural vascular 
remodelling, contributing to sustained HT after adrenalectomy. However, our results 
did not show this, despite the association between long-standing HT and low cure rate 
that has been shown in several other studies (210, 213). Not all our patients had PA 
subtype determined with AVS, and may theoretically have been incorrectly 
adrenalectomised. However, we found no difference in HT cure rate between 
adrenalectomised patients with and without AVS-confirmed unilateral disease. All 
the operated patients with persistently elevated ARR at follow-up had AVS-
confirmed lateralisation before adrenalectomy, but nearly half had histopathological 
hyperplasia. Those patients presumably therefore had asymmetrical bilateral 
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aldosterone production rather than true unilateral PA. Conversely, and similar to 
several other studies, we found female sex, a histopathological verified adenoma and 
the presence of KCNJ5 mutations to be associated with cure of HT (209, 214, 215). 
The better outcome in females is not understood, but may reflect a vasoprotective role 
of estrogens before menopause.  
5.5 Myocardial changes in PA 
CMR offers an accurate, non-invasive 3-dimensional assessment of cardiac structure, 
function and tissue characteristics. Former echocardiographic studies have shown that 
PA is associated with increased LV mass and LV hypertrophy compared with 
essential HT with similar BP levels, with a significant decrease in LV mass both after 
adrenalectomy and after long-term medical treatment with MR antagonists (74, 75, 
207).  
In Paper III, using CMR we similarly found a significant regression in LV mass 
after relatively short time (median 18 months) of specific PA treatment.  The 
regression in LV mass occurred despite small non-significant reductions in BP, 
underscoring the importance of reducing the aldosterone excess in treating organ 
complications. As several of the patients had already been adrenalectomised or 
initiated MR antagonist treatment in the months preceding the baseline CMR 
evaluation, the true effect of PA treatment on LV mass was probably larger than 
found in our study. Our results are in accordance with another CMR study showing 
significant reduction in LV mass in suspected PA both 3 and 6 months after MR 
antagonist treatment, and underscores that also after MR antagonist treatment, effects 
on LV mass measured by CMR occur earlier than former echocardiographic studies 
have been able to detect (232). 
Based on animal studies and previous imaging studies in humans, the medical 
literature suggests that myocardial fibrosis is a clinical problem in PA. In Paper III, 
surprisingly, we found no evidence of increased myocardial fibrosis in PA patients 
compared with healthy subjects, either with CMR dynamic contrast enhancement 
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technique or with CMR T1 mapping. Moreover, the T1 mapping of both the treated 
and untreated PA groups (PA2 and PA1) showed a tendency towards lower ECV 
values than the healthy subjects, indicating an increased intracellular fraction of the 
LV with more pronounced cardiomyocyte hypertrophy relative to the extracellular 
volume expansion.  
Thus, our results contrast experimental animal studies where aldosterone infusion 
combined with high sodium intake caused histopathological myocardial interstitial 
fibrosis (91). However, human myocardial fibroblasts may differ from rodents when 
exposed to excess aldosterone, and the levels of aldosterone and sodium given in 
rodents under experimental conditions may not reflect the exposure in human PA. An 
association between sodium intake and the detrimental cardiovascular and renal 
effects of aldosterone excess have been demonstrated both in animal studies and 
human PA (91, 135-137). Dietary sodium intake was not measured in our study 
participants, nor was it recorded whether or not the PA patients had been given 
specific dietary counselling in order to reduce sodium intake.   
Only one small human post-mortem study in five patients with suspected PA has 
been performed, showing histological fibrosis in several organs; the myocardium, 
lungs and pancreas (254). The patients of that study were approximately ten years 
older than our patients, and it has been shown that aging is associated with 
progressive fibrosis (255).   
Additionally, echocardiographic videodensitometric and ultrasonic backscatter signal 
analyses found alterations in myocardial texture in PA, suggestive of increased 
collagen deposition and possible fibrosis (79-81). However, CMR is the 
recommended imaging modality for myocardial tissue characterisation. Two former 
CMR studies, both applying contrast enhancement techniques, found evidence of 
myocardial fibrosis measured as higher contrast enhancement in PA when compared 
with essential HT and healthy subjects (98, 99). One of those studies (98) measured 
contrast enhancement as the presence of a non-infarct diffuse pattern of late 
gadolinium enhancement, which is considered a less optimal method to evaluate 
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diffuse myocardial fibrosis (97). We applied the same formula for dynamic contrast 
enhancement as in the other study (99). Our contrasting results despite applying the 
same quantification technique may reflect the fact that none of the existing dynamic 
contrast enhancement quantification is accepted as an optimal universal 
quantification technique (96, 97). The discrepancy of our results may also have been 
caused by possible clinical differences in PA subtypes, ethnicity, gender distribution, 
severity of PA phenotype or severity of HT. Possible differences in dietary sodium 
intake in various studies may represent another confounding factor. 
Ultimately, the fact that the increased incidence of cardiovascular events found in 
untreated PA are reduced to the same level as in essential HT after specific treatment, 
supports that irreversible myocardial fibrosis is not present (83).  
To our knowledge, our study is the first to apply CMR T1 mapping with quantitative 
assessment of ECV for evaluation of diffuse myocardial fibrosis in human PA. We 
thus applied the gold standard parametric mapping technique for evaluation of diffuse 
myocardial fibrosis, as recommended in a newly published consensus statement (95). 
Therefore, based on our results, myocardial fibrosis may not be a significant clinical 
problem in PA if diagnosed and treated within time frames commonly used in clinical 
practice. However, larger human CMR T1 mapping studies should be performed to 
explore possible differences in myocardial texture between PA and essential HT; 
between unilateral and bilateral PA; between low-sodium diet and unrestricted 
sodium diet; between different PA age groups; and before and after specific 
treatment.  
5.6 Methodological considerations 
The main limitation of Paper I is the retrospective design, with retrospective 
collection of baseline data. Not all data were accessible for all patients, and not all 
included patients had a confirmed PA. Thus, some of the patients included without 
confirmatory testing might not have had a genuine PA, which might have brought a 
bias to the results. We did however use strict criteria for inclusion. Additionally, not 
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all patients had subtype determined by AVS. The high proportion of patients with 
hypokalaemia and unilateral disease may also have affected the representativeness of 
our study cohort.  
The retrospective design with old age and low quality of some of the pathology 
specimens entailed that not all the adrenal specimens could be determined for somatic 
mutations other than KCNJ5. A significant proportion of specimens could not be 
determined for mutations in ATP1A1, ATP2B3 and CACNAID mutational status, 
which most likely influenced the prevalence of these mutations found in our study 
cohort. 
However, the one-centre design is a strength, with all AVS procedures performed by 
a few radiologists at the same site with the same criteria for selectivity index and 
lateralisation index during the whole study period. Similarly, all the adrenal images 
and histopathological slides were reevaluated by one radiologist and one pathologist, 
both experienced in their fields. Additionally, all outcome data for Paper I were 
prospectively collected by the same physician, under standardised conditions.   
In Paper II, the previous AVS procedures used as historical controls had all been 
performed by the same radiologists as during the study period. This was done in order 
to minimise the risk of bias related to different radiologists during the study and 
control period. However, our study design with a historical control group cannot 
definitely prove the hypothesis that intraprocedural cortisol assays increases AVS 
success rates, and the results from the ongoing randomised I-Padua study are 
therefore awaited (249) 
The time span between AVS procedures with intraprocedural point-of care cortisol 
was shorter than for the previous AVS procedures serving as controls, which might 
have caused an enhanced training effect and therefore may represent a potential 
confounder.  
Paper III was planned as a pilot CMR study for assessment of myocardial fibrosis, 
and relatively small sizes of all study groups may have had the potential for false 
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negative conclusions. However, it is important that also trials with negative results 
are published, to avoid a publication bias. For the PA patients, due to CMR 
contraindications, no patients with a history of coronary arterial bypass surgery were 
included, neither were patients with chronic atrial fibrillation, due to potential 
difficulties with CMR image acquisition. Exclusion of PA patients with those 
comorbidities might have caused a selection bias towards a healthier subgroup of PA 
patients included in the study. Patients with paroxysmal or radiofrequency ablated 
treated atrial fibrillation were included.  
The lack of a control group with essential HT poses a further limitation to Paper III, 
especially where differences between PA and controls were found. A supplementary 
control group of patients with essential HT could have discriminated between 
aldosterone excess or haemodynamic effects of HT per se as causes of differences 
between PA and healthy subjects.  
We originally planned for both a control group of healthy subjects and a control 
group with essential HT. However, at our University hospital there is no HT 
outpatient clinic, and such patients had to be recruited from the cardiology and 
nephrology outpatient clinics, where patients without either severe heart disease of 
renal failure were hard to find. The dead-line of the recruitment period was also 
limited by the replacement of the original CMR scanner in June 2014. By then we 
had only managed to recruit and perform CMR in four patients with essential HT, 
mostly recruited from private cardiologists. Due to the low number these patients 
were excluded from further study analysis.  
The intraprocedural point-of-care cortisol assay applied in Paper II was chosen due 
to its relatively short time required to complete analyses. Additionally, the instrument 
was small enough to fit on to the limited amount of bench space available in the 
vicinity of the radiologist. Comparison of the intraprocedural point-of-care assay was 
performed with the routine immunological assay employed in the laboratory, and 
with cortisol measured by LC-MS/MS. Correlation analyses showed satisfactory 
quality compared with both these methods.  
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The design of Paper III with two different CMR scanners used for the baseline 
CMR1-CE and the follow-up CMR2-T1 sub-studies poses a potential limitation to 
this study, in that direct comparisons of these two methods simultaneously were not 
possible. For the dynamic contrast enhancement quantification used for sub-study 
CMR1-CE, no universally accepted optimal technique exists (97), which may limit 
these results. However, in sub-study CMR2-T1, we applied T1 mapping with ECV 
quantification, which is the gold standard parametric mapping technique (95). On the 
other hand, the application of two different CMR techniques both showing similar 
results strengthens our results, indicating that this particular group of PA patients did 
not have more cardiac fibrosis than the healthy controls.  
The post-image analyses were only blinded for one of two investigators, as these 
analyses were performed by the same investigator that had included all the patients 
and controls and created the identification key. However, Bland-Altman plots found 
deviations of less than 10% between the values obtained by the investigators, which 
was considered acceptable. 
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6 Conclusion and future perspectives 
6.1 Conclusion 
Paper I 
 One hundred and eight diagnosed PA patients were identified in Western 
Norway from 1998-2012, reflecting potentially several thousand undiagnosed 
individuals.  
 The majority of PA patients had unilateral disease and a history of 
hypokalaemia, indicating that particularly normokalaemic and bilateral PA 
remained undiagnosed.  
 The proportion with bilateral PA increased during the study period, pointing 
towards an increased ability to detect bilateral disease.  
 Concordance between adrenal imaging and AVS was low.  
 Somatic KCNJ5 mutations were found in 30% of adrenal specimens, and were 
associated with female sex and a florid PA phenotype.  
 Cure rate of HT after adrenalectomy was low. Female sex, a verified adenoma 
and KCNJ5 mutations were associated with cure of HT.  
Paper II 
 Intraprocedural point-of-care cortisol analysis improved the success rate of 
AVS.  
 A training effect among the radiologists performing AVS with intraprocedural 
cortisol analysis was observed, reducing the need for repeated samples.  
 Correlations between the intraprocedural cortisol assay and the routine cortisol 






 Specific PA treatment rapidly reduced LV mass measured by CMR, most 
prominent after adrenalectomy.  
 No evidence of increased myocardial fibrosis was found in PA compared with 
healthy subjects, measured by CMR dynamic contrast enhancement or T1 
mapping with ECV quantification.  
 Both treated and untreated PA patients had lower T1 mapping ECV values 
compared with healthy subjects, indicating more pronounced cardiomyocyte 
hypertrophy than fibrosis in PA.  
   
Taken together, our findings reflect that most likely PA is still grossly 
underdiagnosed in Norway, in particular the often less florid bilateral IHA. The 
current diagnostic work-up is laborious and requires expert centres. However, after 
introduction of intraprocedural point-of-care cortisol analysis permanently introduced 
at our centre in 2013, the success rate of AVS has increased substantially. Delayed 
diagnosis and high morbidity and mortality are common, but decrease rapidly with 
correct treatment. Cardiac fibrosis may not represent a common clinical problem in 
PA, if diagnosed and treated in due time. Continuous emphasis on identification of 
patients with PA is needed, so that early diagnosis and targeted treatment can be 
initiated in far larger groups of patients. 
6.2 Future perspectives 
Several major challenges must be faced in order to optimise the future management 
of PA. Primary care physicians should be educated and convinced to screen for PA in 
hypertensive patients at risk for PA. However, currently wide variations exist in the 
diagnostic criteria and management of PA between centres. Hence, there is a need for 
harmonisation of screening procedures and diagnostic testing with standardised 
assays in order to minimise these variations. Furthermore, it would be desirable if the 
diagnostic work-up could be simplified without the need of a strict drug withdrawal 
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regime or without the need of AVS, restricted to specialised centres, as subtype 
testing in all patients. This will be increasingly important if the number of patients 
with PA escalates as predicted.  
To this end, we are studying whether analysis of aldosterone levels and rhythm in 
subcutaneous fluid might have merit. We have developed an ambulant microdialysis 
technique allowing for dynamic measurement of hormone levels in subcutaneous 
fluid collected through a microdialysis catheter, and analysed by LC-MS/MS. This 
sampling can be done continuously for 27 hours, thus enabling characterisation of the 
circadian and ultradian rhythms of subcutaneous free aldosterone levels. After initial 
technical difficulties and extensive testing for two years, we have so far successfully 
sampled 13 PA patients with this technique, and included them in our ongoing project 
“Aldosterone rhythm in PA and healthy people”. This study is part of a larger 
multicenter study (the Ultradian study) involving the Endocrinology Departments at 
Karolinska University Hospital Stockholm, the University Hospital of Bristol, and the 
University Hospital in Athens. The Ultradian study is part of the EU Framework 
Programme for Research and Innovation Horizon 2020. 
There is increasing evidence that PA also exists in normotensive individuals and that 
PA represents a continuum. As patients with low-renin HT show the same beneficial 
effects of MR antagonists both on BP and organ complications as patients with overt 
PA, MR antagonist treatment might become first choice treatment also in these 
patient. Finally, the pathophysiological mechanisms leading to bilateral IHA 
constituting the majority of PA patients, should be further elucidated with genetic and 
immunohistochemical studies. This might open new paths for diagnostics and 
therapy.  
Since the beginning of this PhD work in 2013, I have prospectively registered all 
newly diagnosed PA patients attending Haukeland University Hospital. We have 
created an infrastructure for systematic diagnostics, follow-up, and collected blood, 
urine and adrenal tissue in biobanks. Furthermore, we have strengthened our 
collaboration with other units (Stavanger University Hospital, Haugesund Hospital, 
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St. Olav’s Hospital, and Tromsø University Hospital). So far, more than 200 PA 
patients have been registered, with an increased proportion of AVS-confirmed 
bilateral PA compared with in our retrospective cohort from Paper I (unpublished 
data). This infrastructure, with ongoing registration and bio-banking, provides a solid 
platform for future research on PA that may provide further insight into PA and 
improve the care of these patients.  
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Primary aldosteronism (PA) is a common cause of secondary hypertension and is caused by
unilateral or bilateral adrenal disease. Treatment options depend on whether the disease is
lateralized or not, which is preferably evaluated with selective adrenal venous sampling
(AVS). This procedure is technically challenging, and obtaining representative samples
from the adrenal veins can prove difficult. Unsuccessful AVS procedures often require
reexamination. Analysis of cortisol during the procedure may enhance the success rate.
We invited 21 consecutive patients to participate in a study with intra-procedural point of
care cortisol analysis. When this assay showed nonrepresentative sampling, new samples
were drawn after redirection of the catheter. The study patients were compared using the
21 previous procedures. The intra-procedural cortisol assay increased the success rate from
10/21 patients in the historical cohort to 17/21 patients in the study group. In four of the
17 successful procedures, repeated samples needed to be drawn. Successful sampling at first
attempt improved from the first seven to the last seven study patients. Point of care cortisol
analysis during AVS improves success rate and reduces the need for reexaminations, in
accordance with previous studies. Successful AVS is crucial when deciding which patients







Primary aldosteronism (PA) is a common cause of secondary
hypertension; the prevalence is 2–15% in selected cohorts
of hypertensive patients (1, 2, 3, 4, 5). Patients with PA have
higher cardiovascularmortality andmorbidity than controls
with essential hypertension, possibly due to the presence
of mineralocorticoid receptors in the heart and large vessels
(2, 6). In w30–50% of the patients, the disease is unilateral,
caused by for instance aldosterone-secreting adenomas,
whereas the rest have bilateral disease (2, 6, 7, 8). The clinical
management of PA depends on whether the disease is
lateralized. Most patients with unilateral adenomas are
either cured or have significant improvement of their
hypertension after adrenalectomy (9). If the adrenal
hypersecretion of aldosterone is bilateral, or a patient is
unwilling to undergo surgery, medical treatment with a
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Selective adrenal venous sampling (AVS) is the rec-
ommended method to determine whether aldosterone
hyper production is lateralized (10). When recommended
diagnostic cutoff values are used, the sensitivity and
specificity for detecting unilateral disease are 95 and
100%, respectively. In comparison, adrenal computed
tomography (CT) has sensitivity and specificity at 78%
and 72–75% respectively (7, 11). During AVS, blood
samples are drawn from the right and left adrenal veins as
well as a peripheral vein. The ratio between cortisol
measured in the samples taken from the putative adrenal
veins and the peripheral blood sample is most commonly
used to determine whether the sample is representative for
adrenal vein blood (12). A recent study has suggested,
however, that metanephrine might be a better marker of
correct catheter placement (13). The procedure is techni-
cally challenging, and reported success rates range from 8
to 97% (11, 14, 15, 16). It is particularly demanding to
obtain a representative sample from the right adrenal vein
due to anatomic reasons (16). Although the left adrenal
vein drains to the left renal vein, and hence is more easily
identified, the right adrenal veinmostlydrainsdirectly into
the vena cava and with a steep angle. The procedure might
also be complicated by the collapse of the adrenal vein due
to the gentle vacuum applied to obtain the sample.
In traditional AVS protocols, the cortisol levels in the
blood samples are determined after the patient has left
the examination room. Recently, four prospective studies
have shown increased success rate when the sampling
procedure was guided by intra-procedural rapid assay
measurements of cortisol (17, 18, 19, 20). A retrospective
study has showed that diagnostic centers that introduced
suchmeasurements when revising their AVS protocols had
more improvement over time in success rates than
diagnostic centers that did not (14). The published studies
were all small, and used different study protocols. The
cortisol gradient required to deem a sample representative
of adrenal vein blood ranges from two- to fivefold. In the
studies that used cosyntropin to stimulate cortisol
production, the required cortisol gradient ranges from
three- to fivefold. The number of procedures performed by
each radiologist is variable, and different instruments have
been used. Only one study analyzed cortisol using a point
of care instrument (20). This study showed proof of
concept of intra-procedural cortisol measurements, but
included five patients and no control group. In the three
studies including retrospective controls, the samples were
analyzed in the main laboratory (17, 18, 19) or two
patients were examined sequentially to minimize the total
time used for the procedure (17, 18, 19).
We wanted to determine the success rate of AVS
using intra-procedural, point of care cortisol analysis
and compare with a historical AVS series, applying
recommended criteria for sample selectivity (12).
Subjects and methods
Patients
Patients planned for AVS at the Department of Medicine,
Haukeland University Hospital were sent invitation to
participate in the study. The previous 21 AVS procedures
were used as controls. All patients in the study period
provided written consent. The study was approved by the
Regional Ethics Committee for Medical Research (REK-
Vest #2012-01856) and is registered at Clinicaltrials.gov
with accession code NCT01761344. One patient experi-
enced adverse effects after the procedure, and has provided
written consent for this to be reported.
Adrenal venous sampling
AVS was conducted sequentially under continuous
cosyntropin infusion at a dose of 50 mg/h. The infusion
was started 30 min before the procedure was initiated. For
most procedures a Simmons 2/3 catheter was used to draw
samples from the left adrenal vein whereas Hook,
Simmons 2/3, or Shepherds hook catheters were used to
draw samples from the right adrenal vein. A side hole was
made in some catheters to decrease the vacuum at the tip
of the catheter, and a gentle vacuum was applied to draw
samples. For some procedures, a 0.014 inch floppy tip wire
was inserted to prevent the adrenal vein from collapsing
due to the applied vacuum. One to five blood samples were
drawn from the external iliac vein and the putative left
and right adrenal veins. The samples were transferred to
Li/Heparin tubes for the point of care cortisol assay and
serum tubes for routine assays. The sheath was not
removed before the results of the point of care cortisol
assay were available. If the assay revealed that the samples
were not representative, repeated samples were drawn.
The procedure was terminated after the third attempt to
obtain representative samples or when the radiologist
terminated due to increased risk of complications.
Intraoperative cortisol analysis
Cortisol was analyzed at point of care using the AIA-360
Cort-pac system (TOSOH Bioscience, Tokyo, Japan)
according to the protocol provided by the manufacturer.
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at 4440 g for 2 min. The samples were analyzed for cortisol
undiluted and at 1/20 and 1/39 dilution (in cortisol-free
serum provided by the assay supplier). We used a cutoff
ratio of 5:1 between adrenal venous sample and peripheral
sample to determine whether the sample was representa-
tive for adrenal blood as described in reference (12).
Routine analysis
Serum cortisol was analyzed using Immulite 2000
(Siemens, Erlangen, Germany) according to the supplier’s
protocol and an inhouse multisteroid LC-MS/MS assay
(21). The Siemens Immulite system automatically dilutes
samples at 1/5 if the signal exceeds 1380 nmol/l, and
sampleswere analyzed at 1/10, 1/20, and 1/40 sequentially.
For LC-MS/MS analysis, all samples were diluted 1/50 in
steroid-depleted serum (SunnyLab, Sittingbourne, UK)
using an automated pipetting system (Hamilton Microlab
Star, Bondzau, Switzerland). Aldosterone was detected
using a RIA assay (Coat-a-count Aldosterone, Siemens).
As criteria for lateralization, we used aldosterone:cortisol
ratio in adrenal venous sample on one-side four times
greater than that on the other side (12).
Statistical analysis
P values were determined by applying two-tailed Fisher’s
exact test, Student’s t-test, or Wilcoxon’s signed-rank test.
A P value of!0.05 was considered statistically significant.




The clinical characteristics of the patients in the study
cohort and controls are shown in Table 1. Notably, most of
the patients had been diagnosed with hypertension
several years before AVS was carried out. The prevalence
of hypokalemia, as defined by serum potassium values
below the reference limits or use of oral potassium
supplements, was higher than what has been reported
from several other diagnostic centers (6, 22, 23). Some
patients had developed hypokalemia several years before
the diagnosis of PA was made (not shown). Among the
study patients, seven had previously undergone an
unsuccessful AVS, the corresponding number in the
historical series was three. The two groups were not
significantly different with regard to age, ratio between
women and men, and number of patients who had
undergone an unsuccessful AVS previously. The relative
contribution from the two radiologists who conducted
the procedures was similar in the two groups.
Adrenal venous sampling
Representative adrenal venous samples were obtained
bilaterally in 17 of the 21 study patients (81%), whereas
the procedure was successful in only ten of the 21
historical controls (48%) (Fig. 1A). The increased success
rate was due to a significant increase in correct sampling
from the right adrenal vein (Fig. 1B; PZ0.0431). The
success rate of left AVS was unchanged (Fig. 1C).
The first set of samples was representative for 13 of the
study patients, and the first resampling resulted in
representative samples from four additional patients,
for three of which resampling from the right
adrenal vein was required. Of the four unsuccessful
procedures, renewed sampling was done twice in two
patients, whereas the procedure was terminated due
to increased risk of complications after the second
sampling in two of the patients. Seven of the study
patients had previously undergone an unsuccessful
procedure. The procedure was successful for six of these
(not shown).
Table 1 Clinical and procedure characteristics of patients










Age (years) (median and range) 54 (39–77) 55 (30–69)
Days since the radiologist’s
previous procedure (median
and range)
28 (2–147) 7 (1–110)
Samples taken at primary attempt
(median and range)
4 (3–6) 5 (4–9)
Months of known hypertension
(median and number of
patients)
96 (nZ15) 150 (nZ19)
Patients with hypokalemiaa (%) 76 81
Blood pressure at admission
(median)
164/102 162/101
Number of antihypertensive usedb
(mean and range)
3 (2–5) 3 (1–6)
Lateralized/bilateral disease 6/4 13/4
aPatients were considered hypokalemic if they used potassium supplements
and/or had a blood potassium level below the reference range upon
admission to AVS.
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We also observed an increased success rate without
repeated sampling throughout the study period. Whereas
two of the seven first procedures were successful without
renewed sampling, six of the final seven patients did not
require repeated sampling (Fig. 2). The mean time from
patient arrived the radiology suite until procedure was
terminated was 138 min. The mean timespan before the
first set of samples was drawn was 88 min (data not
shown). In the procedures where the first set of samples
was representative, the mean timespan from the acqui-
sition of the last sample till the procedure was completed
was 18 min. One of the patients in the study group was
readmitted to hospital due to persistent pain. CT did not
show ongoing bleeding, but a small amount of fluid was
observed around a diffusely edematous right adrenal
gland. The patient was treated conservatively, and was
discharged without sequelae. No other adverse effects were
noted in the study population or the historical series.
Assay performance
The technical specifications of the point of care cortisol
assay used during the AVS procedures are presented in the
Supplementary Section, see section on supplementary
data given at the end of this article. Briefly, the cortisol
concentrations measured by the intraoperative cortisol
assay correlated well with that obtained using a routine
immunological cortisol assay (Fig. 3 and Supplementary
Figure 1C–E, see section on supplementary data given at
the end of this article) or an LC-MS/MS protocol
(Supplementary Figure 1F). The average bias between the




















































































Numberof patientswhosefirst set of sampleswas representative for adrenal
venous blood (white columns), representative samples were obtained
before the procedure was terminated (gray columns) or representative
samples were not obtained (black columns). (A) Data for both adrenal veins,

























Number of patients whose first set of samples was representative for
adrenal venous blood (white columns), representative samples were
obtained before the procedure was terminated (gray columns), or where
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Discussion
We found that after implementation of intra-procedural
point of care cortisol analysis, the success rate of AVS
procedures increased from 48% in the control period to
81% in the study period. This was due to an increase in the
success rate of right AVS. There was a trend toward
increased number of successful procedures without the
need of resampling over the study period. The increased
success rate can be attributed both to the opportunity to
draw a new set of samples, as was done successfully in four
patients, as well as a training effect for the radiologists.
All previously published studies have shown significant
increased success rate after repeated sampling (Table 2)
(17, 18, 19). The trend toward increased success of initial
sampling throughout the study period reproduces the
results of Betz et al. (19). In our study, there was, however,
a higher proportion of patients undergoing their second
AVS among the first seven of the study patients. The
uneven distribution of these patients might constitute a
confounder to the observed training effect. However, there
was no significant difference between the successful
sampling of patients undergoing first and repeated
procedures (not shown). We therefore find this to be an
unlikely confounder. It is difficult to differentiate between
the training effect due to shorter time interval between
procedures in the study period and the effect of the point
of care cortisol analysis. This also applies to the study
by Betz et al. (19), where the intervention group was
examined over a shorter time period than the controls.
A shorter time span between procedures may thus
represent a potential confounder in both studies.
Of the previously published studies on intra-
procedural cortisol measurements during AVS, only the
study reported by Rossi et al. (17) required a fivefold
cortisol gradient for successful sampling. In that study, a
single radiologist performed all 25 AVS. In the current
study, all the 21 procedures were performed by two
radiologists. We used an approach where the length of
the procedure was kept at a minimum, and the patient was
not moved to recovery before resampling, as described in
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Comparison of results of point of care plasma cortisol and routine serum
cortisol. (A) Correlation between p-cortisol in the point of care assay and
s-cortisol in the routine assay. Open circles were included in the correlation
analysis, closed circles were considered outliers. (B) Difference between the
two assays as a percentage of the mean cortisol concentration.
Table 2 Prospective studies of intra-procedural cortisol analysis during AVS. The cortisol selectivity ratio is the ratio of cortisol






















Betz (19) 26/47 25/46 39/46 No O2 LIAISON-Kit 3 0/1
Rossi (17) 16/25 19/25 23/25 Yes O5 LIAISON-Kit 1 0/0
Auchus (18) 22/30 27/30 29/30 Yes O3 Avida Centaur 5 0/0
Presented study 10/21 13/21 17/21 Yes O5 Tosoh AIA 360 2 0/1
Total 74/123 84/122 108/122 0/2
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limit patient discomfort. Despite this, the radiology suite
was only occupied for a mean 50 min after the first set of
samples was drawn, 18 min if the first set of samples was
representative. In comparison, Rossi et al. used 200 min to
examine two patients if both procedures were successful.
Although there areno randomized trials showing effect
of intra-procedural cortisol assay during AVS, four pro-
spective studies, including this study, have shown
increased success rate upon implementation of cortisol
measurements (Table 2) (17, 18, 19). The increased success
rate is independent of whether cosyntropin is used, the
cortisol gradient required to deem the sample representa-
tive, the assay employed, and the number of procedures
conductedby the individual radiologist in the studyperiod.
No published trials showing negative results have been
identified. In total, including this study, two patients have
had serious complications and required prolongedhospital
stay or readmission to hospital. Neither patient has
experienced further sequelae.Of the 123 patients subjected
to AVS with intra-procedural cortisol analysis, this gives a
complication rate of 1.6%,which isnot significantlyhigher
than what is reported for the procedure in general (7).
All published prospective studies are from centers
with intermediate initial success rates (range 48–73%). The
accumulated evidence for utilizing intra-procedural corti-
sol assays during AVS at centers with success rates!75% is
compelling. Implementing the assay increases the quality
of patient care by reducing the need for repeated
procedures. The rate of complications is not significantly
increased compared to protocols without point of care
cortisol measurements.
Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/
EC-13-0063.
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Supplementary section:
Description of the point of care cortisol assay
TOSOH AIA360 was chosen as the point of care instrument due to the relatively short time required
to complete analysis, and as the instrument would fit on the limited amount of bench space
available. TOSOH AIA360 utilizes fluorescence enzyme immunoassay as the mode of detection and
sufficient analytical quality had been shown in a previous study (1). After the samples were loaded
into the analyzer the first results were available after 20 minutes, with one sample analyzed every
1.5 minutes. With sample centrifugation and dilution, the results were available 25 30 min after the
sample was obtained. The results of the point of care assay were compared with the routine assay
employed in the laboratory (Siemens Immulite 2000). The CV% of the point of care assay using one
lot of reagents was 7,5 13,2 % using controls provided by the supplier and 4,3 5,4 % using Li Heparin
plasma spiked with cortisol. The CV% of diluted plasma samples were 13 20%.
The correlation between cortisol measured in plasma and serum on the point of care instrument was
linear (figure S1, panel A), with an average bias of 7.4 % (95% KI for bias: 10.5% to 4.5 %). Serum
samples run on the point of care instrument and the routine instrument showed linear correlation
(figure S1, panel B) without significant bias (95 % KI 1.1% to 15.3%). Plasma cortisol measured by the
point of care assay correlated well with the serum values of cortisol measured by the routine
immunological assay (figure 3a, figure S1, panels C E). Although the bias was comparable between
undiluted samples and samples diluted 1/20 ( 13 % and 14 % respectively), the observed bias was
lower for samples diluted 1/39 ( 1,8%). This last point needs to be taken into account when
evaluating these samples, and might be due to increased inaccuracy of the pipette at lower volumes
as well as a decreased effect of the plasma matrix in more dilute samples. The direct measurements
of cortisol in serum by LC MS/MS also correlated well with point of care plasma measurements of
cortisol (figure S1, panel F). The average bias was 2,6 % (n.s). The concentration of cortisol in plasma
samples was not determined by LC MS/MS.
As a conclusion the assay had satisfactory quality compared to the routine methods employed. The
results from highly diluted samples must be assessed with care.
1. Mengozzi G, Rossato D, Bertello C, Garrone C, Milan A, Pagni R, Veglio F & Mulatero P. Rapid
cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clinical Chemistry
2007 53 1968 1971.
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Abstract
Background: Primary aldosteronism (PA) is associated with increased cardiovascular 
morbidity, presumably due to left ventricular (LV) hypertrophy and fibrosis. However, the 
degree of fibrosis has not been extensively studied. Cardiac magnetic resonance imaging 
(CMR) contrast enhancement and novel sensitive T1 mapping to estimate increased 
extracellular volume (ECV) are available to measure the extent of fibrosis.
Objectives: To assess LV mass and fibrosis before and after treatment of PA using CMR 
with contrast enhancement and T1 mapping.
Methods: Fifteen patients with newly diagnosed PA (PA1) and 24 age- and sex-matched 
healthy subjects (HS) were studied by CMR with contrast enhancement. Repeated 
imaging with a new scanner with T1 mapping was performed in 14 of the PA1 and 20 
of the HS median 18 months after specific PA treatment and in additional 16 newly 
diagnosed PA patients (PA2).
Results: PA1 had higher baseline LV mass index than HS (69 (53–91) vs 51 (40–72) g/m2;  
P < 0.001), which decreased significantly after treatment (58 (40–86) g/m2; P < 0.001 
vs baseline), more with adrenalectomy (n = 8; −9 g/m2; P = 0.003) than with medical 
treatment (n = 6; −5 g/m2; P = 0.075). No baseline difference was found in contrast 
enhancement between PA1 and HS. T1 mapping showed no increase in ECV as a 
myocardial fibrosis marker in PA. Moreover, ECV was lower in the untreated PA2 than HS 
10 min post-contrast, and in both PA groups compared with HS 20 min post-contrast.
Conclusion: Specific treatment rapidly reduced LV mass in PA. Increased myocardial 
fibrosis was not found and may not represent a common clinical problem.
Introduction
Primary aldosteronism (PA) has been recognized as the 
most common cause of secondary hypertension (HT), 
with estimated prevalence of 5–12% of all hypertensive 
subjects (1, 2). In patients with refractory HT, PA may be 
present in up to 20% (3). Unilateral aldosterone-producing 
adenoma (APA) and bilateral idiopathic hyperplasia (IHA) 
are the main subtypes; unilateral hyperplasia, inherited 
familial forms of PA and adrenal carcinoma are rare (4). 
Recommended treatment is adrenalectomy in unilateral 
PA and medical treatment with mineralocorticoid receptor 
antagonists in bilateral PA.
Several studies have demonstrated that PA patients 
have increased cardiovascular and renal morbidity 
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Indeed, a recent study also demonstrated increased 
cardiovascular mortality (9). Increased prevalence of 
diabetes mellitus type 2 and the metabolic syndrome 
may also be present (10). Aldosterone, often associated 
with cortisol excess, causes deleterious effects on the 
cardiovascular system and increases metabolic risk, with 
end-organ damage that is at least partly independent 
of aldosterone effect on blood pressure (BP) (11). 
Experimental rat studies first demonstrated that 
chronic aldosterone infusion in the setting of high-salt 
intake induced oxidative stress and caused myocardial 
inflammation, accumulation of fibrillary collagen and 
subsequent interstitial fibrosis independent of the BP 
elevation (12, 13, 14). The cardiac injury was reversed 
either with adrenalectomy or mineralocorticoid receptor 
antagonist treatment (15). Subsequent echocardiographic 
studies have demonstrated increased left ventricular (LV) 
mass in PA compared with essential HT with similar BP (16). 
Echocardiographic videodensitometric and ultrasonic 
backscatter signal analyses have shown alterations in 
myocardial texture in PA, suggestive of increased collagen 
deposition and fibrosis (17, 18, 19). PA patients have more 
cardiac arrhythmias than in essential HT, presumably 
caused by cardiac fibrosis and/or LV hypertrophy (5, 20).
Specific PA treatment decreases LV mass both 
after adrenalectomy and after medical treatment with 
mineralocorticoid receptor antagonists in the long term, 
while echocardiographic studies with shorter follow-up 
time only showed significant reduction in LV mass after 
adrenalectomy (21, 22). In a recent meta-analysis, no 
difference in reduction of LV mass was found between 
adrenalectomy and mineralocorticoid receptor antagonist 
treatment after an average follow-up of four years, despite 
a larger reduction in BP after adrenalectomy (23).
Cardiac magnetic resonance imaging (CMR) 
offers a highly accurate, non-invasive, 3-dimensional 
assessment of cardiac structure, function and tissue 
characteristics. Contrast enhancement techniques 
including late gadolinium enhancement are accurate 
and reproducible in evaluating the presence of 
irreversible focal myocardial fibrosis/scars caused by 
myocardial infarction or hypertrophic cardiomyopathy 
(24, 25). Contrast enhancement is associated with 
adverse outcomes in several cardiac conditions 
(26, 27). However, the most commonly used 
contrast enhancement technique, late gadolinium 
enhancement, requires a comparison between affected 
and unaffected myocardium and may not be sensitive to 
early, potentially reversible diffuse myocardial fibrosis 
affecting the whole myocardium (28).
Recently, T1 mapping techniques assessing T1 
relaxation times have allowed quantitative assessment 
of tissue composition and detection of both focal and 
diffuse interstitial myocardial fibrosis. T1 mapping 
performed before and after administration of 
gadolinium-based contrast media allows quantification 
of the extracellular volume (ECV), a surrogate measure 
for the extracellular space, which is expanded in 
myocardial fibrosis due to interstitial accumulation of 
collagen type I and III (28, 29).
Two CMR studies applying contrast enhancement 
techniques have revealed results consistent with 
increased myocardial fibrosis in PA, but only one 
applied a quantification technique for enhancement 
assessment (30, 31). One CMR study addressed the 
effect of medical mineralocorticoid receptor antagonist 
treatment in PA on cardiac volume overload and 
LV hypertrophy, with mineralocorticoid receptor 
antagonist treatment causing significant decreases in 
both LV mass and cardiac volumes (32). Further, CMR 
with T1 mapping has been used to evaluate the effect 
of HT and subsequent treatment with spironolactone 
on interstitial myocardial fibrosis in mice (33). Thus, 
the extent of fibrosis induced by PA and its reversibility 
is still incompletely known. We therefore aimed to 
assess myocardial mass and fibrosis in PA, using both 
dynamic contrast enhancement and T1 mapping, 
before and after adrenalectomy or medical treatment 
with mineralocorticoid receptor antagonist.
Subjects and methods
Study participants and design
This study was performed between October 2013 and 
March 2016 at Haukeland University Hospital, Bergen. 
Fifteen patients with recently confirmed PA (PA1) and 
24 age- and sex-matched normotensive healthy subjects 
(HS) were included for baseline CMR with dynamic 
contrast enhancement (CMR1-CE) between October 
2013 and June 2014 (Fig.  1). After completion of this 
substudy, they were invited to a follow-up CMR with 
T1 mapping (CMR2-T1, June 2015–March 2016), 
performed at least one year after the start of specific PA 
treatment. One patient was excluded from follow-up 
due to deterioration of renal function and four HS 
declined follow-up. An additional 17 newly diagnosed 
patients (PA2) were recruited of whom 16 completed the 
protocol.
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Diagnosis and clinical assessment
All PA patients had their diagnosis confirmed by saline 
infusion testing (SIT), and adrenal vein sampling (AVS) 
for subtype differentiation planned or performed at the 
time of study inclusion, according to current guidelines 
(4). Positive SIT was defined as a post-infusion plasma 
aldosterone level >140 pmol/L (34, 35). BP was measured 
in a standardized manner in all study groups, with three 
repetitive measurements in a seated position, after at least 
five minutes rest. Height and weight were recorded for all.
CMR performed with dynamic contrast 
enhancement (CMR1-CE)
PA1 and HS were examined with a 3T GE Signa Excite 
Scanner (Milwaukee, WI, USA). A phased-array cardiac 
coil with eight elements was used. All images were 
obtained during breath-hold with electrocardiography 
(ECG) triggering. For evaluation of LV mass and LV 
volumes, short-axis CINE views were obtained, using a 
Fiesta sequence. A pre-contrast mid-ventricular short-
axis view and a 4-chamber view were then performed 
before a gadolinium-based contrast agent (Gadovist 
1 mmol/mL, Bayer Pharma AG) 0.2 mL/kg body weight 
was administered as an intravenous bolus injection. An 
inversion recovery gradient echo sequence was applied. 
Contrast images in the same views as pre-contrast were 
then acquired at seven consecutive time points (2, 4, 6, 8, 
10, 12 and 14 min) post-contrast.
CMR performed with T1 mapping (CMR2-T1)
The scanner used for the CMR1-CE was replaced in June 
2014. The CMR2-T1 substudy was therefore performed 
with a 3T Siemens Magnetom Skyra (Erlangen, Germany). 
All images were obtained during breath-hold with ECG 
triggering. CINE views were performed using the same slice 
parameters as for the baseline CMR1-CE. The inversion 
recovery-based MOLLI sequence was used for T1 mapping 
(MyoMaps; Siemens, Erlangen) in accordance with the 
recommendations of the Society for Cardiovascular 
Magnetic Resonance (SMR) (36, 37). A native pre-contrast 
T1 mapping mid-ventricular short-axis view was then 
performed before the gadolinium-based contrast agent 
(Gadovist 1 mmol/mL, Bayer Pharma AG) 0.15 mL/kg body 
weight was administered as an intravenous bolus injection. 
Further T1 mapping mid-ventricular short-axis views were 
then performed 10, 15 and 20 min post-contrast.
Figure 1
Study flow chart for the three study groups; PA1, HS and PA2. CMR1-CE, cardiac magnetic resonance imaging with dynamic contrast enhancement; 
CMR2-T1, cardiac magnetic resonance imaging with T1 mapping; HS, healthy subjects; PA1, primary aldosteronism group 1; PA2, primary aldosteronism 
group 2.
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ECG, oxygen saturation and pulse were monitored 
continuously during all CMR procedures. BP was measured 
regularly during all image sequences.
Estimation of LV mass, volumes and function
For estimation of LV mass, LV volumes and function, 
the CMR images were analysed by using the software 
Segment, version 1.9 R3697 (http://segment.heiberg.se) 
(38). End-diastole and end-systole were defined and LV 
endo- and epicardial borders were manually delineated 
in all slices in end-diastole and end-systole (excluding 
papillary muscles). Values for LV mass, LV end-diastolic 
volume (LV-EDV), end-systolic volume (LV-ESV), stroke 
volume (LV-SV), cardiac output (CO) and ejection fraction 
(EF) were then calculated, and mass and volumes were 
indexed to body surface area.
Estimation of myocardial fibrosis from contrast 
enhancement images
For the contrast enhancement image acquisition, a 
protocol earlier published by Su and coworkers was 
adopted and slightly modified (31). From mid-ventricular 
short-axis views performed pre- and at the different time 
points post-contrast, three non-overlapping regions of 
interest (ROI) were placed both in the interventricular 
septum and within the LV lumen (Fig. 2A). The average 
signal intensities (SI) both from the interventricular 
septum and the lumen were calculated. The contrast 




SI post-contrast myo SI native − myo
SI post-contrast blood SI native blood−
SI post-contrast myo is the SI of myocardium after 
contrast, SI native myo is the SI of myocardium before 
contrast, SI post-contrast blood is the SI within the LV 
lumen after contrast and SI native blood is the SI within 
the lumen before contrast.
Estimation of myocardial fibrosis  
from T1 mapping
T1 mapping measurements were performed using syngo.
via software (Siemens, Erlangen). One ROI covering 
most of the interventricular septum and one ROI within 
the LV lumen were drawn both from the native pre-
contrast T1 mapping and the post-contrast T1 mapping 
short-axis views (Fig. 2B). The ECV was then calculated as 


















CMR imaging of the heart. (A) Post-contrast short-axis view of the heart 
with three ROIs drawn in the interventricular septum and lumen for 
calculation of contrast enhancement values (substudy CMR1-CE). (B) 
Post-contrast T1 mapping short-axis view of the heart with a ROI drawn 
in the interventricular septum and lumen for calculation of ECV 
(substudy CMR2-T1). CMR1-CE, cardiac magnetic resonance imaging with 
dynamic contrast enhancement; CMR2-T1, cardiac magnetic resonance 
imaging with T1 mapping; ECV, extracellular volume; ROI, region of 
interest.
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 T1 post-contrast myo is the SI of myocardium after 
contrast, T1 native myo is the SI of myocardium before 
contrast, T1 post-contrast blood is the SI within the LV 
lumen after contrast and T1 native blood is the SI within 
the lumen before contrast.
All post-processing measurements for both CMR1-CE 
and CMR2-T1 were performed by two investigators (MG/KS 
or MG/TL), and the mean values of the measurements from 
the two investigators were used for statistical analyses.
Statistical analysis
All parameters are expressed as median and ranges. Student’s 
t-test and Mann–Whitney U test were used to compare
normally and not normally distributed continuous data
between two groups, and Wilcoxon signed-rank test for
within-patient not normally distributed data. One-way
ANOVA was used to compare continuous data between
more than two groups. For comparison of categorical
variables, the chi-square test or Fisher’s exact probability
test was used. Bland–Altman plots were used for analysing
the agreement between the measurements performed
by the two investigators. A deviation of less than 10%
between the values obtained by the two investigators
was considered acceptable. P values less than 0.05 were
considered statistically significant.
Written informed consent was obtained from all 
participants. The study was approved by the Regional 
Committee for Medical and Health Research Ethics 
(REC West/University of Bergen).
Results
Clinical characteristics: CMR with dynamic 
contrast enhancement (CMR1-CE)
The clinical characteristics of PA1 and HS at the time of 
the baseline CMR1-CE are shown in Table 1. PA1 and HS 
did not differ in terms of age or sex, but the PA1 patients 
had higher body mass index (BMI) and higher BP than 
the HS (median BMI 26 (range 22–34) vs 23 (18–27) kg/m2; 
P < 0.001 and BP 138/90 vs 118/75 mmHg; P < 0.001 for 
both systolic and diastolic BP).
In PA1, AVS performed for subtype differentiation 
showed unilateral PA in 9/15 patients, the remaining had 
bilateral (5/15) or not representative (1/15) AVS. Three PA1 
patients had been adrenalectomized within the past three 
months prior to inclusion for CMR1-CE. Five had started 
medical mineralocorticoid receptor antagonist treatment 
within the past 4–7 months, while the remaining had not 
yet started specific PA treatment.
One patient in PA1 had established coronary disease 
at baseline (paroxysmal atrial fibrillation). One had 
experienced several cerebral infarctions before the age 
of 50 years. Two had diabetes mellitus type 2, and two 
had chronic kidney disease, with estimated glomerular 
filtration rates of 47 and 54 (mL/min/1.73 m2) at baseline, 
respectively. One PA patient without a history of coronary 
disease had sequelae from a small cardiac infarction found 
on his CMR. He was referred for cardiac evaluation.
Clinical characteristics: CMR with 
T1 mapping (CMR2-T1)
For PA1, the CMR2-T1 was performed at least one 
year after the start of specific treatment either with 
unilateral adrenalectomy or medical treatment with 
mineralocorticoid receptor antagonists (Table  1). Eight 
of 14 PA1 patients had been adrenalectomized, with 
median 18 (range 12–21) months since adrenalectomy. 
The remaining 6/14 were on medical mineralocorticoid 
receptor antagonist treatment, with median 21 (12–27) 
months since start of this medication. BP at follow-up 
was still significantly higher in the PA1 than in the HS 
group (median BP 134/81 vs 124/73 mmHg; systolic 
BP P = 0.02/diastolic BP P = 0.012), despite a median 
two antihypertensive drugs in the PA1 group. In PA1, 
only small non-significant BP changes appeared after 
treatment, with median systolic BP reduction 7 mmHg; 
P = 0.064 and median diastolic BP reduction 5 mmHg; 
P = 0.148 (not shown).
Among the 16 newly diagnosed patients in PA2 
performing CMR2-T1, AVS showed unilateral disease in 
six patients and bilateral in 10 (Table 1). Only one of the 
newly diagnosed PA patients in PA2 had started specific 
PA treatment with spironolactone two months before the 
CMR2-T1; none in PA2 had yet been adrenalectomized. 
One of the PA2 patients had ischaemic coronary disease 
treated with percutaneous coronary intervention as 
comorbidity, two had atrial fibrillation (one paroxysmal 
and one radiofrequency ablated), and one had diabetes 
mellitus type 1. Median BP was 145/91 mmHg in PA2, 
with median three (0–6) antihypertensive drugs.
LV function and LV mass: CMR with dynamic 
contrast enhancement (CMR1-CE)
The results from LV function and LV mass measured 
with CMR1-CE are listed in Table  2. Baseline LV mass 
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indexed to body surface area differed significantly 
between the PA1 and HS group (LV mass index 69 (53–91) 
vs 51 (40–72) g/m2; P < 0.001). No differences between 
the two groups were found in cardiac function measured 
as LV-EDV index, LV-ESV index, LV-SV index, LV-EF, HR 
or CO index.
Dynamic contrast enhancement 
results (CMR1-CE)
Figure  3 illustrates the contrast enhancement values in 
PA1 and HS measured from 2 to 14 min post-contrast. 
No difference was found in contrast enhancement value 
between PA1 and HS at any time point. For both PA1 and 
HS, the contrast enhancement showed a trend towards 
reduced values from 2 to 14 min post-contrast.
LV function and LV mass-CMR with T1 
mapping (CMR2-T1)
LV function and LV mass indexes for PA1, HS and PA2 
measured with CMR2-T1 are shown in Table  2. At 
follow-up CMR2-T1, PA1 had a significantly reduced LV 
mass index (LV mass index 58 (40–86) g/m2; P < 0.001 vs 
baseline values). LV mass index in PA1 was still higher, 
but no longer significantly different to LV mass index 
in HS (LV mass index 58 (40–86) vs 57 (45–75) g/m2; 
P = ns). When analysing the adrenalectomized (n = 8) 
Table 1 Clinical and biochemical characteristics of PA1, HS and PA2 at substudy CMR1-CE and substudy CMR2-T1.*
CMR1-CE CMR2-T1
PA1 HS PA1 post-treatment HS PA2
Participants in study group, n 15 24 14 20 16
Characteristics
Males:females 12:3 17:7 11:3 13:7 12:4
Age (years) 58 (34–72) 53 (34–70) 59 (36–68) 53 (35–71) 57 (29–72)
Body mass index (kg/m2) 26 (22–34) 23 (18–27) 26 (23–35) 22 (19–29) 29 (19–36)
Duration of hypertension (years) 15 (2–25) 0 10 (0–25)
Systolic blood pressure (mmHg) 138 (123–178) 118 (100–136) 134 (105–180) 125 (105–136) 145 (123–182)
Diastolic blood pressure (mmHg) 90 (60–108) 75 (61–88) 81 (69–105) 75 (60–94) 91 (75–115)
Number of antihypertensive drugs (n) 3 (0–5) 0 2 (0–6) 0 3 (0–6)
Biochemistry
Hypokalaemia (n)** 14 7
Lowest s-potassium measured (mmol/L) 3.0 (2.3–3.7) 3.6 (2.5–4.0)
S-potassium (mmol/L) 3.3 (2.8–4.4) 4.3 (3.8–5.3) 3.7 (3.3–4.7)
P-aldosterone (pmol/L) 680 (384–2252) *** 412 (57–3420) 293 (116–855) 490 (277–2110)
P-renin activity (µg/L/h) 0.1 (0.1–3.0) *** 0.8 (0.2–26.7) 1.7 (0.3–4.0) 0.4 (0.1–0.8)
ARR (pmol/µg/h)**** 6065 (168–22,520) 288 (21–2650) 224 (53–662) 1580 (610–3700)
Direct renin concentration (mIE/L)**** 2.2 (2.0–8.2)
ARR (pmol/mIE)**** 126 (46–1055)
Post-SIT aldosterone at diagnosis (pmol/L) 348 (169–1144) 297 (167–1460)
AVS results PA patients
AVS lateralization (n) 9 8 6
AVS non-lateralized (n) 5 5 10
AVS not representative (n) 1 1 0
Treatment status PA patients
Adrenalectomized (n) 3 8 0
Months since adrenalectomy 2.5 (0.5–3.0) 18 (12–21)
MR antagonist treatment (n) 5 6 1
Spironolactone (daily dose in mg) 50 (25–100) 50 (25–75) 25
Eplerenone (daily dose in mg) 100 (n = 1)
Months since start MR antagonist treatment 6 (4–7) 21 (12–27) 2
Not started specific treatment (n) 7 0 15
*Data shown as median (range) or as number; **hypokalaemia was defined as s-potassium <3.5 mmol/L at least once; ***p-aldosterone and p-renin 
activity in the healthy subjects (HS) were measured at the time of the CMR2-T1; ****ARR calculated with plasma renin activity: normal range <750 pmol/
µg/h. The renin assay was in February 2016 changed from plasma renin activity (Gammacoat, Diasorin) to direct renin concentration (LIAISON Direct 
Renin, DiaSorin). 7/16 of the patients in the PA2 group therefore had their renin measured as direct renin concentration. ARR calculated with direct 
renin concentration: normal range <50 pmol/mIE with aldosterone <300 pmol/L, normal range <35 pmol/mIE with aldosterone >300 pmol/L.
ARR, aldosterone–renin ratio; AVS, adrenal vein sampling; CMR1-CE, cardiac magnetic resonance imaging with dynamic contrast enhancement; 
CMR2-T1, cardiac magnetic resonance imaging with T1 mapping; HS, healthy subjects; MR antagonist, mineralocorticoid receptor antagonist; PA1, 
primary aldosteronism group 1; PA2, primary aldosteronism group 2; SIT, saline infusion test.
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and the medically treated (n = 6) PA1 patients separately, 
the adrenalectomized patients had a larger and highly 
significant reduction of LV mass index, compared with the 
medically treated patients who showed a trend towards, 
but had no significant reduction in LV mass index 
(adrenalectomized PA1 median reduction of LV mass 
index −9 g/m2; P = 0.003 vs mineralocorticoid receptor 
antagonist treated PA1 reduction of LV mass index −5 g/m2; 
P = 0.075, not shown).
The newly diagnosed PA2 group had significantly 
higher LV mass index at CMR2-T1 than both the treated 
PA1 and HS (PA2 median LV mass index 70 (50–92); 
P = 0.019 vs treated PA1; PA2 vs HS P < 0.001).
For PA1, LV-EDV index showed a non-significant 
trend of reduction from baseline CMR1-CE to follow-up 
CMR2-T1 (P = 0.076). In the HS group, LV-EDV 
remained unchanged (Table  2). When comparing the 
adrenalectomized vs medically mineralocorticoid receptor 
antagonist-treated PA patients, only the PA1 patients 
treated with mineralocorticoid receptor antagonists had a 
significant reduction in LV-EDV index (medically treated 
PA1 median change in LV-EDV index −14 mL/m2; P = 0.03, 
vs adrenalectomized PA1 −7 mL/m2; P = 0.54 (not shown)).
T1 mapping results (CMR2-T1)
The results from the T1 mapping performed with CMR2-T1 
for both treated PA1, newly diagnosed PA2 and HS are 
shown in Fig. 4. No increase in ECV as a CMR marker of 
interstitial fibrosis was found in either PA1 or PA2 compared 
with HS. On the contrary, ECV was significantly lower in 
the untreated PA2 than in the HS 10 min post-contrast, 
and in both PA groups compared with the HS group 20 min 
post-contrast. No significant difference in ECV was found 
between PA1 and PA2 at any time-point post-contrast.
Discussion
In this study, we applied CMR to explore the effects of PA, 
before and after treatment, on myocardial morphology 











P value PA1 
vs HS 
(CMR1-CE)**
P value PA1 
post-treatment 





PA1 (n = 15)
 
 






HS (n = 20)
 
 
PA2 (n = 16)
LV-EDV index (mL/m2) 85 (72–109) 91 (62–120) 79 (61–104) 91 (76–121) 97 (69–116) ns ns
LV-ESV index (mL/m2) 33 (20–52) 37 (24–51) 31 (20–47) 37 (23–54) 38 (19–51) ns ns
LV-SV index (mL/m2) 53 (33–68) 53 (38–73) 48 (33–66) 53 (36–72) 57 (49–86) ns ns
LV-EF (%) 62 (45–74) 62 (52–67) 60 (48–73) 60 (42–71) 62 (51–74) ns ns
HR (beats/min) 64 (39–87) 66 (50–84) 63 (44–80) 53 (38–66) 54 (42–68) ns ns
CO index (L/min/m2) 3.5 (2.2–4.4) 3.5 (2.3–5.0) 2.6 (2.0–4.5) 3.0 (1.9–4.0) 3.1 (2.0–4.8) ns ns
LV mass index (g/m2) 69 (53–91) 51 (40–72) 58 (40–86) 57 (45–75) 70 (50–92) <0.001 <0.001
*Data shown as median (range); **Student’s t-test used.
CO, cardiac output; CMR, cardiac magnetic resonance imaging; CMR1-CE, cardiac magnetic resonance imaging with dynamic contrast enhancement; 
CMR2-T1, cardiac magnetic resonance imaging with T1 mapping; EDV, end-diastolic volume; EF, ejection fraction; ESV, end-systolic volume; HS, healthy 
subjects; LV, left ventricular; PA1, primary aldosteronism group 1; PA2, primary aldosteronism group 2; SV, stroke volume.
Figure 3
Box plots of dynamic contrast enhancement distribution at 2–14 min 
post-contrast for PA1 and HS (substudy CMR1-CE). The horizontal line 
indicates the median, the box represents the 25th–75th percentiles, and 
the whiskers represent the minimum and maximum value. Circles and 
asterisk indicate outliers. CMR1-CE, cardiac magnetic resonance imaging 
with dynamic contrast enhancement; HS, healthy subjects; PA1, primary 
aldosteronism group 1.
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and function. The myocardial hypertrophy observed 
at diagnosis rapidly normalized with treatment, most 
pronounced after adrenalectomy. However, surprisingly 
neither dynamic contrast enhancement nor T1 mapping 
revealed myocardial fibrosis in newly diagnosed PA 
compared with HS.
The finding of lack of increased myocardial fibrosis 
in PA contrasts both earlier experimental studies 
and human ultrasonographic backscatter signal and 
videodensitometric studies (12, 13, 17, 18, 19). However, 
CMR is the recommended imaging modality for 
myocardial tissue characterization, and our findings also 
contrast two former 1.5 Tesla CMR studies using contrast 
enhancement techniques, which both showed higher 
contrast enhancement in PA than in essential hypertensive 
patients and healthy controls (30, 31). However, in one of 
these studies (30), contrast enhancement was measured 
as the presence of a non-infarct diffuse pattern of LGE, 
which is a less objective method to evaluate diffuse 
myocardial fibrosis (28). The other study used the same 
formula for dynamic contrast enhancement as we (31). 
However, there is still no universally accepted optimal 
dynamic contrast enhancement quantification technique, 
which may be reflected in the discrepancy of our results 
despite applying the same technique (28, 39). The PA 
patients in the two former studies were slightly younger 
than both our PA groups, but had a similar duration of 
HT. Possible differences in PA subtypes, severity of PA 
phenotype, gender distribution or severity of HT might 
also have influenced our discrepant results.
The recent developments of T1 mapping techniques 
enable quantitative assessments of changes in myocardial 
tissue composition and the presence of diffuse myocardial 
fibrosis, with estimation of the ECV percentage. T1 
mapping thus facilitates a non-invasive alternative 
to myocardial biopsies and histochemical analyses 
(40). If myocardial fibrosis is present, expansion of the 
extracellular interstitial space should yield higher ECV. 
ECV has been shown to correlate well with histological 
fibrosis in several cardiac diseases (28), and this is the 
first time this technique is used to study PA. Similar to 
dynamic contrast enhancement, T1 mapping showed no 
evidence of increased myocardial fibrosis. In contrast, 
we found that both the newly diagnosed and treated PA 
group in our study had, at 20 min post-contrast, lower 
ECV than the healthy subjects. Thus, the left ventricular 
intracellular fraction is increased, which indicates 
more pronounced cardiomyocyte hypertrophy than 
ECV increase in both PA groups. Our findings clearly 
challenge the widely held conception that substantial 
myocardial fibrosis is typical in PA. Myocardial interstitial 
fibrosis caused by aldosterone and salt loading has been 
histologically proven in experimental animal studies (12, 
41, 42). Human myocardial fibroblasts may differ from 
rodents when exposed to excess amounts of aldosterone, 
and the experimental levels of aldosterone and sodium in 
rodents may not reflect the exposure in humans with PA. 
To our knowledge, only one small human post-mortem 
study of five patients of high age with adrenal adenomas 
with suspected PA due to concomitant HT and low or low-
normal s-potassium levels has been performed. That study 
showed histological fibrosis both in the myocardium as 
well as in the pancreas and lungs (43). However, ageing is 
associated with progressive fibrosis (44), and in the former 
study, the patients were approximately ten years older than 
in our study. Moreover, significant fibrosis may well be an 
end stage of long-standing and untreated PA. Furthermore, 
the fact that risks of cardiovascular complications in 
untreated PA are reduced to the same level as in essential 
HT after specific PA treatment, supports that irreversible 
fibrosis is not present (20). Essentially, this is the first study 
Figure 4
Box plots of the ECV distribution from T1 mapping at 10, 15 and 20 min 
post-contrast for PA1 (post-treatment), PA2 (newly diagnosed) and HS 
(substudy CMR2-T1). The horizontal line indicates the median, the box 
represents the 25th–75th percentiles, and the whiskers represent the 
minimum and maximum value. *P < 0.05 vs HS. CMR2-T1, cardiac magnetic 
resonance imaging with T1 mapping; ECV, extracellular volume; HS, 
healthy subjects; PA1, primary aldosteronism group 1; PA2, primary 
aldosteronism group 2.
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to apply CMR T1 mapping with quantitative assessment of 
ECV, which is the recommended gold standard parametric 
mapping technique for evaluation of diffuse myocardial 
fibrosis in a newly published consensus statement (37).
We also measured the effect of PA treatment on LV mass 
index and found a significant reduction after treatment. 
Regression of LV hypertrophy is associated with improved 
cardiovascular outcome in essential HT (45). When 
analysing the adrenalectomized and medically treated 
PA patients separately, reduction of LV mass index was 
highly significant only for the adrenalectomized group. 
Although not significant, we observed a strong trend 
towards reduction of LV mass index also in the medically 
treated group, with a median follow-up time of less than 
two years. These findings are in accordance with another 
CMR study, which showed significant regression of LV 
mass index in patients with suspected PA both after 3- 
and 6-month treatment with mineralocorticoid receptor 
antagonists (32). One echocardiographic study showed 
no significant change of LV mass index one year after 
start of mineralocorticoid receptor antagonist treatment, 
whereas another large study showed borderline significant 
reduction in LV mass index in medically treated PA after 
a median follow-up of 36 months (21, 22). The regression 
in LV mass after specific PA treatment occurred despite no 
significant reduction in BP. In the Framingham Offspring 
study, the aldosterone-to-renin ratio was identified as a 
key correlate of LV hypertrophy (46). Studies conducted 
in patients with essential HT have similarly shown a direct 
relationship between aldosterone levels and changes in 
LV geometry (47, 48). Thus, the reduction of LV mass after 
PA treatment is probably due to both reduced aldosterone 
levels and improved BP.
In the PA patients, we found a significant reduction 
in LV-EDV index only in the medically treated subgroup, 
in accordance with a former study (32). PA is associated 
with increased plasma brain natriuretic peptide and 
intracardiac volume overload, which is reversed by 
mineralocorticoid receptor antagonists or adrenalectomy. 
In the former study, the intracardiac volume overload was 
refractory to thiazides, while low doses of spironolactone 
showed a prominent diuretic effect. Small numbers may 
explain why no difference was found in LV-EDV index in 
the adrenalectomized patients in the current study.
A limitation of our study is that not all PA1 patients were 
completely treatment naïve at the time of the CMR1-CE; 
some had already undergone adrenalectomy and some had 
commenced treatment with mineralocorticoid receptor 
antagonists shortly before. Among the newly diagnosed 
PA2 patients participating in the CMR2-T1, only one 
patient had started specific PA treatment shortly before 
his CMR. PA patients with unilateral disease often have a 
more florid phenotype, and the relatively large proportion 
of patients with bilateral disease in PA2 may represent a 
less severe form of PA, which may have influenced the T1 
mapping results.
The lack of an additional hypertensive control 
group is a limitation. If evidence of increased myocardial 
fibrosis in PA compared with in healthy subjects had 
been found, such a control group would have been 
necessary to determine whether these changes were 
caused by aldosterone excess or haemodynamic effects 
of hypertension itself. Furthermore, it could have shown 
whether the lower ECV in both treated and untreated 
PA post-contrast would be caused by aldosterone or 
haemodynamic effects of hypertension per se.
The replacement of the CMR scanner used at baseline 
with a new scanner for the follow-up CMR2-T1, may 
pose a further limitation. On the other hand, the use 
of two different techniques to study myocardial fibrosis 
with overlapping results certainly strengthens the study. 
A further asset is that all post-image analyses were 
performed by two different investigators. A limitation is 
that the dynamic contrast enhancement technique and 
T1 mapping were applied at different time points of the 
study, and we were therefore unable to examine the study 
participants with these two methods simultaneously, 
which would have given direct comparisons of the two 
methods. The PA1 patients had all received specific 
PA treatment for at least a year when examined with 
T1 mapping but were relatively treatment naïve when 
examined with dynamic contrast enhancement, which 
precludes direct comparisons of contrast enhancement 
and T1 mapping results in this group. In order to examine 
treatment-naïve PA patients with T1mapping, we 
therefore included also the newly diagnosed PA2 group 
for the CMR2-T1.
Habitual dietary sodium intake of the study 
participants was not recorded, and it is unknown whether 
the PA patients had been given specific dietary counselling 
to reduce their salt intake prior to or during the study 
period. In experimental animal studies, high levels of 
aldosterone infusion did not cause cardiovascular damage 
when sodium intake was very low (12). Similarly, in 
humans, extraordinarily high aldosterone concentrations 
in populations with chronic sodium deficiency was not 
associated with cardiovascular damage (49). A recent 
study demonstrated that dietary salt intake influenced 
the reduction of LV mass after PA treatment (50). Thus, 
dietary sodium intake may have influenced our results.
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In conclusion, specific PA treatment rapidly reduced 
LV mass. Both dynamic contrast enhancement and, 
notably, the recommended T1 mapping, showed no 
evidence of increased myocardial fibrosis in PA patients 
compared with healthy individuals. Thus, myocardial 
fibrosis does not seem to be a significant clinical problem 
in PA if diagnosed and treated within time frames 
commonly used in clinical practice.
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